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                                             Abstract  
Diabetes is an endocrine disease characterised by a chronic increase in blood sugar 
levels caused by a deficiency of insulin production, which leads to type 1 diabetes, or 
by a loss of tissue response to insulin, which leads to type 2 diabetes. The disease 
leads to disruption of metabolism, vascular damage and damage to the nervous 
system, as well as damage to other organs and systems. Type 2 diabetes is 
becoming more common throughout the world, due to poor nutrition and lifestyle, 
and genetic background. Efforts have accordingly been increased towards 
developing and refining treatments as well as to addressing the underlying causes of 
the disease. Many parts of the world have a documented history of the use of plants 
to treat diabetes, and these can be an attractive, local, alternative to expensive 
pharmaceutical medicines. Accordingly there is an increasing interest in identifying 
new phytochemicals with proven pharmacological effects on diabetes.  
The tree Moringa peregrina is commonly found throughout the Middle East and the 
oil from its seeds has been used for thousands of years. Other members of the 
Moringa family have recorded anti-diabetic family and Moringa peregrina was 
chosen for investigation in this work with the aim of characterising anti-diabetic 
activity from its leaves. Six extracts were prepared using solvents water, methanol, 
butanol, ethyl acetate, chloroform and hexane, based on standard extraction 
techniques. The study was designed to assess the effect of these six extracts on the 
uptake of glucose in a human hepatoma cell line (HepG2) using a well-studied 
fluorescent derivative of glucose, 2-2-[N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino 
glucose (2-NBDG). The cells can take up 2-NBDG instead of glucose via glucose 
transporters and its uptake is indicative of the capacity of cells to take up glucose, 
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i.e. of the number of active glucose transporters on the cell surface. The results 
revealed that the extracts prepared with ethyl acetate and chloroform increased 
glucose uptake significantly more than the other extracts. Moreover the effects of the 
extracts were rapid, with a one hour treatment producing a similar stimulation to a 24 
hour treatment. These data were confirmed in a second method of investigation of 
the hypoglycaemic effect of the extracts, by measuring consumption of glucose from 
cell culture medium.  A preliminary assessment of the effect of active extracts on 
expression of the main glucose transporter of HepG2 cells, GLUT1, by western 
blotting indicated no large changes in expression. 
Dietary phytoestrogens have been shown to play a beneficial role in obesity and 
diabetes, so the second part of this study investigated the effect of phytoestrogens 
on glucose uptake. Three phytoestrogens (daidzein, formonontein and genestin, 
which are naturally occurring isoflavones) were chosen. HepG2 cells showed a 
significant increase in glucose uptake after treatment with phytoestrogens compared 
to the control.  
In an attempt to identify the active phytochemicals that could account for the 
observed effects, extensive purification and characterisation of components from the 
ethyl acetate fraction was undertaken. Seven components were identified: (1) O-
Ethyl 4-[(α-L-rhamnosyloxy)benzyl] thiocarbamate (E), (2) O-Butyl 4-[(α-L-
rhamnosyloxy)benzyl] thiocarbamate (E), (3) 4-(α-L-Rhamnosyloxy)benzyl 
isothiocyanate, (4) ȕ-Sitosterol, (5) Daucosterol, (6) γ’-methyl-quercetin-3-O-
rutinoside (also known as isorhamnetin-3-O-rutinoside), (7) Rutin. 
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In a final analysis an attempt was made to assess the effect of a representative set 
of three out of the seven components on basic metabolic activity of HepG2 cells 
using a Seahorse XF-24 analyser. The three components chosen were O-ethyl 4-[(α-
L-rhamnosyloxy) benzyl] thiocarbamate (E),  ȕ-sitosterol from the phytosterols family 
and Rutin. Real-time monitoring of cell metabolism by a Seahorse XF-24 auto 
analyser after two hours incubation with the three chosen compounds revealed that 
maximal respiration, non-mitochondrial respiration and spare respiratory capacity 
have trended towards an increase with ȕ-sitosterol and3-O-ethyl 4-[(α-L-
rhamnosyloxy) benzyl] thiocarbamate (E) treatments compared to control. As no 
similar trends were observed in ATP production, the increased maximal respiration 
could increase metabolic activity at higher concentrations of glucose and account, in 
part for the effects observed on glucose consumption. 
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Diabetes mellitus (DM) is a metabolic disorder characterised by hyperglycaemia and 
interruption of the metabolism of protein, carbohydrate and fat. It may be associated 
with distinctive symptoms, such as polyuria (frequent urination), polydipsia 
(increased thirst) and polyphagia (increased hunger). 
DM is an important public health concern that affects more than 170 million 
individuals worldwide. It is expected that the number of people suffering from 
diabetes in the UK will reach approximately 5 million, or almost 10% of the 
population, by 2025 and it is one of the leading causes of death worldwide (Islam et 
al. 2009; UK Diabetes Association, 2014). Diabetes is a multi-organ disease 
independent of age, race and gender. A number of pathogenic actions are involved 
in the progress of diabetes, including destruction of the beta cells of the pancreas, 
which leads to insulin deficiency. Some of the processes can cause resistance to 
insulin, leading to increased plasma glucose levels and abnormalities of 
carbohydrate, fat and protein metabolism. Diabetes is classified into four groups: 
type 1, type 2, gestational and maturity onset diabetes of the young (MODY). 
Glucose profiles of these are shown in Figure 1.1. 
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Figure 1.1. Spectrum of glucose homeostasis and diabetes mellitus. The spectrum, from normal glucose 
tolerance to diabetes in type 1, type 2, other specific types of diabetes and gestational diabetes, is shown from 
left to right. In most types of diabetes, the individual traverses from normal glucose tolerance to impaired glucose 
tolerance to overt diabetes (these should be viewed not as abrupt categories but as a spectrum). Arrows indicate 
that changes in glucose tolerance may be bidirectional in some types of diabetes. (Adapted from the American 
Diabetes Association, 2007.) 
 
1.1 Glucose metabolism 
Glucose is a chemical substance that can be obtained from the diet and from 
endogenous pathways. From a chemistry point of view, it is a simple sugar that 
belongs to the group of monosaccharide carbohydrates and is one of the main 
energy sources for both plants and animal cells. Disaccharides such as lactose (a 
combination of glucose and galactose) and sucrose (a combination of glucose and 
fructose), and polysaccharides such as starch, a branched polymer of glucose are 
other types of carbohydrates and are also sources of glucose (Fox et al. 2003). The 
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main metabolic pathways of glucose in energy metabolism are outlined in Fig. 1.2. 
Glucose crosses cell membranes through glucose transporters, mainly members of 
the GLUT family of transporters, though which glucose moves by diffusion down a 
concentration gradient. Once taken up by cells, glucose enters the glycolytic 
pathway. The initial step is phosphorylation to glucose-6-phosphate by hexokinase 
or glucokinase, depending on the tissue.  The conversion of glucose to glucose-6-
phosphate prevents glucose leaving the cell, which it could do through the GLUT 
transporters if the diffusion gradient was reversed. Galactose also enters the 
glycolytic pathway after conversion to glucose-6-phosphate. Fructose can be 
converted to fructose-6-phosphate and then enter the glycolytic pathway. 
Glycolysis produces pyruvate, which can enter the mitochondrial pathway of ATP 
generation after conversion to acetyl-CoA. Alternatively, under anaerobic conditions 
pyruvate is reduced to lactate which is then excreted by the cell. 
Alternatively, and particularly in liver and muscle, glucose can be stored as glycogen, 
when cellular demands for ATP are low.  The liver is also able to synthesise glucose 
in a reversal of glycolysis in the gluconeogenesis pathway (Fig. 1.2). 
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Figure 1.2 A summary of metabolism. Carbohydrate metabolism starts with digestion in the small 
intestine, where glucose (monosaccharide) is absorbed into the blood stream and the metabolism of 
glucose starts after uptake into cells.  
The process of glucose metabolism is regulated by glucoregulatory hormones, which 
include insulin, glucagon, amylin, GLP-1, glucose-dependent insulinotropic peptide 
(GIP), epinephrine, cortisol and growth hormones. Of these, insulin and amylin are 
derived from the beta cells of the pancreas, glucagon from the alpha-cells of the 
pancreas, and GLP-1 and GIP from the L-cells of the intestine (Aronoff et al. 2004).  
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1.2 Glucokinase 
 
Glucokinase (GK), also known as human hexokinase IV, or hexokinase D, is one 
member of a group of ATP:D-hexose 6-phosphotransferases, and this form is 
expressed in the liver and pancreas. It has a high Km for glucose and is active when 
glucose levels are high. It acts as a glucose sensor enzyme that controls 
carbohydrate metabolism in the liver, or as described above, insulin secretion from 
the pancreas. Glucokinase is not inhibited by its product glucose-6 phosphate, while 
other hexokinases are inhibited, and hence glucokinase is able to take part in a 
pathway of stimulating insulin release in response to increased glucose levels 
(Matschinsky 1996; Prokopenko et al.2009). It is possible that modulation of 
glucokinase activity could be one way in which anti-diabetic agents work. Insulin can 
stimulate liver glucokinase in a glucose-independent manner and perhaps some 
phytochemicals can mimic this action (Iynedjian et al. 1989).  
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1.3 Insulin 
 
Structure  
Insulin is produced in the beta cells of the Islets of Langerhans in the pancreas. It is 
a peptide hormone and the name comes from the Latin word insula, meaning island.  
Insulin synthesis starts with the production of preproinsulin from which the  
prohormone precursor, proinsulin is produced. Proinsulin consists of two chains A 
and B with 51 amino acid and the C-peptide with 31 amino acids. There are two 
disulphide connections between chains A and B in proinsulin.  Insulin maturation 
happens after involvement of prohormone convertases 2 and 3 and carboxyl-
peptidase H which facilitate the conversation of proinsulin to active insulin, as shown 
in Fig. 1.3 (Rung et al. 2009). 
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Source: http://faculty.samford.edu/~djohnso2/44962w/405/protsort.html 
Figure 1.3 Insulin biosynthesis. Insulin synthesis starts by cleavage of the signal peptide (SP) in preproinsulin 
that leads to formation of proinsulin. Removal of the connecting peptide assists the insulin maturation process. 
 
Its effect in glucose haemostasis is based on its influence on glucose uptake from 
the general circulation while it has a preventive effect on the body against developing 
the metabolic disease diabetes mellitus, due to inhibition of hepatic 
gluconeogenesis. (Dupuis et al. 2010) 
 
Secretion 
Beta cells produce insulin in two phases; the first is a rapid, triggered phase and the 
second phase is slow release. The rapid triggered phase occurs in reaction to 
different types of factors such as glucose, glucagon-like peptide-1 (GLP-1), glucose-
independent insulinotropic peptide (GIP), adrenaline via 2 receptors, and arginine, 
leucine, acetylcholine and cholecyctokinin (CCK) (Cawston et al. 2010: Layden et al. 
2010). 
 Glucose, as the main triggering factor in releasing insulin, enters pancreatic beta 
cells through the glucose transporter GLUT2, and once inside the cells it is 
converted to glucose-6 phosphate (G6P) via a phosphorylation process by 
glucokinase (hexokinase IV). The process is rate-limiting and is responsible for 
glucose-related insulin secretion. The converted form of glucose, glucose-6-
phosphate, enters glycolysis, in which it forms pyruvate, which then enters the 
pathway for ATP generation in mitochondria via the citric acid cycle. The increased 
influx of glucose into the beta-cells causes an increase in ATP production and hence 
the ratio of ATP/ADP consequently increases, and as a result closes the potassium 
channel which leads to depolarization of the cells. Cell depolarization opens voltage-
12 
 
dependent calcium channels and an influx of calcium into the cell. An increase in 
calcium ion level induces the stimulation of phospholipase C which leads to insulin 
secretion. The pathway is illustrated in Figure1.4 (Gudmundsson et al. 2007; Brunton 
and Chabner 2011; Longo et al. 2011). 
 
 
 
 
 Figure 1.4 How pancreatic cells are induced to secrete insulin.  When levels of glucose in the blood 
increase beyond normal, the flux of glucose into energy production in the pancreatic beta cell increases, resulting 
in an increase in the ratio of ATP/ADP (1). This is sensed by the ATP-sensitive K
+
 channel which closes in 
response (2). K
+
 can no longer flow into the cell and the cell becomes depolarised, an event which opens 
voltage-gated Ca
2+
 channels (3). The increase in intracellular Ca
2+
 triggers release of insulin from pre-formed 
granules in the early phase of insulin release (4). 
© 2010 Nature Education all rights reserved. Adopted from: //www.nature.com/scitable/content/the-key-
steps-leading-to-glucose-stimulated. 
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1.4 Insulin mechanism of action  
 
Insulin induces its effect by binding to the insulin receptors (IR) expressed on the cell 
plasma membrane.  The receptors belong to the tyrosine kinase receptor group and 
in terms of functionality are similar to the insulin-like growth factor-1 (IGF-1) 
receptors (Lyssenko et al.2009).This transmembrane receptor is activated by insulin, 
IGF-I AND IGF-II (Bouatia-Naji et al.2009) and is composed of two subunits, alpha 
and beta, encoded by a single gene, INSR, on chromosome 19 (Miedema et al. 
2005).  Once the tyrosine kinase activity of the receptor is activated a series of 
biochemical pathways are triggered, mediated primarily by activation of insulin 
receptor signalling proteins (IRSs) (Fig. 1.5). Regulation of glucose uptake by 
peripheral tissues involves control of GLUT4 expression (see below), and 
phosphatidyl-inositol  
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Figure 1.5 Insulin signalling pathways. The complexity of insulin signalling is illustrated by this scheme, taken 
from Taniguchi et al.(2007).  
 
3-phosphate kinase (PI3K) plays a central role in mediating insulin signals that inhibit 
gluconeogenesis, stimulate glycogen synthesis and storage and stimulate protein 
synthesis and lipogenesis (Taniguchi et al. 2007). 
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1.5 Glucose Transport 
Glucose is transported into cells through two types of carrier. One type is the Na+-
glucose linked transporter (SGLT) (Wright 2001) and the other are the Na+-
independent sugar transporters (GLUT group) (Mueckler et al.1994). The two groups 
differ in their functionality as well as their structures. 
SGLT types comprise two sub-groups, based on their affinity for glucose. Most are 
high affinity, low capacity transporters and in the kidney the low-affinity, high capacity 
type is expressed as well. In these transporters Na+/K+ ATPase pumps promote 
glucose transport by maintaining the gradient of Na+ needed. SGLTs are expressed 
mostly in small intestine and the proximal tubule of nephrons in the kidney (Wood et 
al. 2003). 
The more widely expressed family are the facilitative glucose transporters (GLUT) 
are transmembrane proteins with 12 membrane –spanning helices that promote 
diffusion of glucose, and other sugars, down concentration gradients across the 
plasma membrane. When glucose attaches to the extracellular site of the 
transporter, a conformational change of the transporter is induced that allows the 
release of glucose from another, intra-membrane, site of the transporter (Hruz et al. 
2001). The GLUT group is divided to three classes (Class I, II, and III) and has 13 
members (Hruz et al. 2001; Joost et al. 2001).  Class I GLUTs include GLUT 1 to 
GLUT4, the most important transporters in tissues affected by insulin signalling 
(Table 1.1). 
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Name Distribution Notes 
GLUT1 Is widely distributed in fatal tissues. In the adult, it is 
expressed at highest levels in erythrocytes and 
also in the endothelial cells of barrier tissues such 
as the blood–brain barrier. However, it is 
responsible for the low level of basal glucose 
uptake required to sustain respiration in all cells. 
Levels in cell membranes are 
increased by reduced 
glucose levels and decreased 
by increased glucose levels. 
GLUT2 A bidirectional transporter, allowing glucose to flow 
in 2 directions. Is expressed by renal tubular cells, 
liver cells and pancreatic beta cells. It is also 
present in the basolateral membrane of the small 
intestine epithelium. Bidirectionality is required in 
liver cells to uptake glucose for glycolysis, and 
release of glucose during gluconeogenesis. In 
pancreatic beta cells, free flowing glucose is 
required so that the intracellular environment of 
these cells can accurately gauge the serum 
glucose levels. All three monosaccharides 
(glucose, galactose, and fructose) are transported 
from the intestinal mucosal cell into the portal 
circulation by GLUT2. 
Is a high-frequency and low-
affinity isoform. There is 
some evidence that GLUT 1 
and 3 are actually the 
functional transporters in beta 
cells. 
GLUT3 Expressed mostly in neurons (where it is believed 
to be the main glucose transporter isoform), and in 
the placenta 
Is a high-affinity isoform, 
allowing it to transport even in 
times of low glucose 
concentrations 
GLUT4 
Found in adipose tissues and striated 
muscle (skeletal muscle and cardiac muscle). 
Is the insulin-regulated 
glucose transporter. 
Responsible for insulin-
regulated glucose storage 
 
 
 
 
Table 1.1 Class I glucose transporters. (Bell et al. 1990 and Thornes et al. 2010) 
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GLUT3 is a very high affinity glucose carrier expressed in the brain, where glucose 
plays important role in central nerve system metabolism (Simpson et al. 2008, 
Vannucci et al. 1997,). 
GLUT4 is the insulin sensitive glucose transporter present in skeletal muscle, heart 
and adipose tissue where it plays a crucial role in controlling levels of postprandial 
plasma glucose rises, where GLUT4 responds to insulin (Rayner et al. 1994). The 
uptake of glucose is rapidly enhanced by insulin via stimulation of GLUT4 
translocation from intracellular vesicles to expression on the cell surface plasma 
membrane in skeletal muscle and adipose tissues (Shepherd et al. 1999).  
Translocation of GLUT 4 can also be stimulated through exercise in skeletal muscle 
tissues, known as insulin independent GLUT4 translocation stimulation (Ploug et al. 
1998). 
GLUT5 is the transporter for fructose and is widely present in intestinal tissue 
(Burant et al. 1992), as well as in kidney, brain, adipose tissue and skeletal muscle. 
This transporter has been a focus for research due to its selectivity for transporting 
fructose. The high level of fructose consumption in the diet suggests the involvement 
of fructose in metabolic disorders such as obesity, diabetes and insulin resistance. 
After uptake into cells, fructose will go through the pathways of ATP production.  
However it has a different metabolic path from glucose and does not increase insulin 
secretion from pancreatic beta cells in the way glucose does (Eliott et al.2002). 
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1.6 History of diabetes research 
In the first century BC, the term diabetes and its diagnoses were given to patients 
with high levels of urine excretion by Greek physicians. Other doctors called diabetes 
“sweet urine disease”, whereby attraction of ants to a person’s urine was a key factor 
in diagnosing diabetes patients. In later stages, the sweet taste of diabetic patients’ 
urine was described by researchers and the word “mellitus” was added to the term 
“diabetes”. 
In 1898, an important discovery after experimental pancreactomy revealed that the 
pancreas plays role in DM. (Minkowski et al.1890) 
Following that, in 1922, Sir Frederick Grant Banting, a Canadian physician, 
announced insulin as a diabetic medication (Liabrary and Archives Canada 2000) 
1.7 Type 1 Diabetes 
Type 1 DM (T1DM) is an organ-specific autoimmune disease causing the selective 
destruction of beta cells of pancreatic islets of Langerhans, leading to progressive 
impairment of insulin production. Failure of insulin production means that control of 
glucose levels is largely lost. Consequently, after a meal, levels of glucose will 
become abnormally high. This in itself does not cause malaise but when 
microvasculature is chronically exposed to high levels of glucose, endothelial cells 
can become damaged and peripheral circulation impaired.  Left untreated, the loss of 
micro-circulation can lead to tissue death at the peripheries, requiring amputation. 
Conversely if glucose levels are not regulated then in times of starvation, or more 
commonly, if food has not been eaten for several hours, then hypoglycaemia can 
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occur.  The brain requires continual minimal levels, about 5 mM, of glucose for 
energy supply.  If levels fall lower than this, even for a short period, brain function is 
impaired, loss of motor control and a state of coma can result. Prolonged 
hypoglycaemia induces utilisation of lipid to provide free fatty acids as a metabolic 
fuel. This can lead to complications, such as diabetic ketoacidosis (DKA) caused by 
the breakdown of adipose tissue, make T1DM a life-threatening condition if left 
untreated (Crawford 1991). 
This condition is also as known as “insulin-dependent DM” (IDDM) or “juvenile 
diabetes” and can be activated by both genetic and environmental factors. This type 
of disease normally develops, and is diagnosed, in childhood and adolescence. It 
can however be diagnosed in adulthood. 
IDDM normally starts at a young age, and presents with social disorders. Once 
diagnosed, patients need lifelong insulin treatment and can experience multiple 
disease-associated complications (Couch et al. 2008). 
The HLA class II allele is the main genetic factor in autoimmune diabetes. The HLA 
locus encodes antigen presenting proteins that help immune cells attack cells 
infected by viruses or, less commonly, by bacteria, or to attack tumour cells. 
Inheriting particular types of HLA genes creates more opportunities for immune cells 
to attack the body’s healthy cells, which leads to autoimmune diseases such as DM 
type 1 (Dean et al. 2004). 
There is currently no cure for T1DM. Promising cures could include transplant of 
beta cells, stem cell therapy, or gene therapy, but require resource intensive 
development to ensure long-term and reliable efficacy and safety. Research both in 
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rodent models of spontaneous diabetes and in humans has improved our 
understanding of the molecular basis of diabetes, and especially the role of the 
insulin receptor and associated signalling proteins (Wu et al. 2013). 
1.8 Type 2 Diabetes 
Type 2 diabetes is a group of progressive disorders characterised by high blood 
glucose levels caused by a lack of insulin activity which can arise from a combination 
of impaired insulin secretion and impaired response to insulin in key tissues and 
organs, known as insulin resistance. One consequence is that gluconeogenesis in 
the liver is no longer inhibited by insulin, and thus increases. 
Insulin resistance means that the body is unable to use insulin efficiently, because 
target tissues become unresponsive to insulin. Type 2 diabetes develops most often 
in middle-aged and older adults, but increasingly is appearing in children, teenagers 
and young adults (Rasooly et al. 2015). It accounts for about 90% of cases of 
diabetes. 
Patients with this type of diabetes may not require insulin to survive. Type 2 diabetes 
is often a result of excess body weight and physical inactivity in genetically 
predisposed individuals and is the most common type (Shojania et al. 2006). 
Genetics and lifestyle are the two main causes of diabetes, and they can lead to 
insulin resistance, impaired insulin secretion, obesity and abnormal fat metabolism 
(Longo et al. 2011)  
Therefore, in the early stage of type 2 diabetes, in response to impaired insulin 
action the level of serum insulin increases (Del Prato et al., 2002). At this time, the 
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cells responsible for production of insulin (pancreatic beta cells) lose their 
functionality due to constant stimulation to recover the insulin output. As a result, 
impaired insulin secretion occurs.  
Numerous studies have proved the association of obesity and weight gain with an 
increased risk of diabetes (Ford et al. 1997; Resnick et al. 2000). 
Research has shown that T2DM is a partially inherited disease. Family studies 
showed that individuals with a negative family history are three times less likely to 
develop the disease compared to those with a positive family history (Flores et al. 
2003; Hansen 2003; Gloyn 2003). 
Identification of disease susceptibility genes has been the focus of intensive 
research. Early studies (Barroso et al., 2003; Stumvoll, 2004) identified the candidate 
susceptibility genes PPARγ, ABCC8, KCNJ11 and CALPN10. 
PPARȖ (peroxisome proliferator-activated receptor-Ȗ) is used as a target for some 
antidiabetic medications, such as thiazolidinediones, because this gene encodes a 
transcription factor important in adipocyte and lipid metabolism.  
UABCC8 (ATP binding cassette, subfamily C, member 8) U and KCNJ11 are targets 
for sulfonylurea drugs and control the secretion of hormones, such as insulin and 
glucagon, by their involvement in the ATP-sensitive potassium channel. Therefore, 
any disturbance in their activities will affect their functionality, which can lead to T2D. 
CAPN10 controls an intracellular calcium-dependent cysteine protease (Cox et al., 
2004). 
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Further studies showed an additional 20 confirmed loci associated with type 2 
diabetes (Zeggini et al. 2008; Dupuis et al. 2010; Qi et al. 2010) and genome-wide 
association analyses that included patients from different ethnic groups have 
confirmed a total of almost 40 loci. These include one locus restricted  to type 2 
diabetes that was one of the first to be identified that has a role in mediating the 
action of insulin rather than its secretion, IRS1 (encoding insulin-receptor substrate 
1) (Rung et al. 2009). The hepatocyte nuclear factors HNF1A and HNF1BI, and 
variants in or near WFS1 (Sandhu et al. 2007; Winckler et al. 2007; Gudmundsson et 
al. 2007; Franks et al.2008) the melatonin-receptor gene MTNR1B (Prokopenko et 
al.2009; Lyssenko et al.2009; Franks et al. 2008) are also implicated.  The current 
state of GWAS findings has been recently reviewed and about 80 genetic loci are 
associated with development of T2D in European populations (Dorajoo et al. 2015).  
These findings have helped to understand the molecular basis of insulin secretion 
and action better, but also indicate genes that can affect treatment effectiveness and 
allow identification of potentially good or poor responders to a given treatment. 
1.9  Other types of diabetes  
In addition to types 1 and 2 diabetes, the two most common forms, other types of 
diabetes have been recognised, that have different aetiologies.  These include 
congenital diabetes, caused by insulin secretion deficiency; cystic fibrosis-related 
diabetes arising as a complication of impaired CFTR function; steroid diabetes, 
which is influenced by high doses of glucocorticoids and gestational diabetes, which 
occurs during pregnancy (Lynn et al. 2012). 
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1.10 Diabetes complications 
Complications related to any type of acute and chronic diabetes are classified into 
two types. Acute effects of short-term disruption in the balance of blood sugar are 
due to 
 
Figure 1.6 Chronic complications arising from diabetes. DM is the main cause of a number of 
serious health conditions, such as cardiovascular disease, blindness, kidney failure and neuropathy 
that leads to lower limb amputation. (Reproduced from international diabetes 
federation).(http://www.idf.org/. international diabetes federation). 
 
either too low or too high levels of glucose. When levels are low, a state of 
hypoglycaemia, diabetic ketoacidosis and nonketotic hypoglycaemic coma can 
occur.  When levels of glucose are too high, diabetic hyperglycaemic hyperosmolar 
syndrome and hyperosmolar hyperglycaemic nonketotic syndrome (HHNS) can 
occur. The acute conditions include ketoacidosis, and hypoglycaemic reactions. The 
chronic complications include retinopathy, nephropathy, neuropathy ( Henry et 
al.1997; Mard-Soltani et al. 2011). 
Chronic complications of DM (Fig. 1.6)  take 10 to 15 years to occur. One major type 
is caused by damage to microvasculature, which can lead to the common 
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complication of diabetic retinopathy, the major cause of blindness in diabetics (Font 
et al., 2004). Another chronic complication is diabetic peripheral neuropathy (DPN) 
caused by damage to sensorimotor and autonomic nerves, and leads to erectile 
dysfunction (impotence) and foot ulcers (Andrew et al. 2005; Chu et al. 2001). 
Another microvascular complication is diabetic nephropathy, which is the most 
common reason for renal failure in countries such as the USA (Fowler, 2011). 
Microvascular damage can also lead to macrovascular complications such as 
ischaemic heart disease, stroke and peripheral vascular disease. Macrovascular 
disease can also develop in the peripheral vasculature and can affect 
cerebrovascular flow (Chew 2006). 
In the case of retinopathy, aldose reductase plays a key role in the pathogenesis.  
This enzyme is involved in the polyol pathway where glucose is converted to sorbitol. 
As glucose levels increase, the conversion of glucose to glucose alcohol (sorbitol) 
will increase as well. Sorbitol accumulation and consequently increased osmotic 
pressure are assumed to be the underlying mechanism in the pathogenesis of 
diabetic retinopathy (Gabbay 1975; Gabbay 2004; Fong et al. 2004).  
Generally the continual, high levels of glucose experienced in untreated diabetes can 
cause generation of advanced glycation end-products in basement membranes of 
microvasculature. Glucose is a reducing sugar and can react, at a very slow rate, 
with proteins and other macromolecules. For example the blood marker for diabetes 
is Hb1Ac, a glycation product of haemoglobin. Glycation will occur more quickly 
when there is an oxidative environment and if protein turnover is slow (Goldin et al. 
2006). The glycation causes cross-linking of proteins and eventually causes cell 
25 
 
dysfunction and local inflammation, deposition of scavenger cells, eventually leading 
to loss of flow and local tissue damage. 
1.11 Diagnostic criteria  
On basis of the information from Diabetes UK, who adopt that the WHO guidelines 
for diagnostic criteria, the following diagnostic categories for diabetes are 
recommended: 
1 Diabetic symptoms such as polyuria, polydipsia and unexplained weight loss 
for Type 1 plus: 
 Random blood glucose level greater than 200 mg/dl (11.1 mM) in the 
presence of diabetes symptom including polydipsia, polyuria and 
polyphagia. 
 Fasting plasma glucose (FPG) level greater than 125 mg/dl (7.0 mM) from 
at least two independent measurements. 
 Two-hour plasma glucose greater than 200 mg/dl (11.1 mM) after 75 g of 
oral glucose load (Oral Glucose Tolerance Test). 
 Haemoglobin A1C (Glycated Haemoglobin) greater than 6.5%. 
 According to studies, a combination test of FPG and A1C is recommend 
for diagnosis of diabetes type (Sato et al.2009). 
2 If diabetic symptoms are not present, then at least two tests need to be done 
to confirm the diagnosis (WHO 1999). There are, however, different 
diagnostic criteria for gestational diabetes, including: 
 A fasting plasma glucose level of 5.6 mM or above or 
 A 2-hour plasma glucose level of 7.8 mM or above (WHO  2006). 
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Glycated haemoglobin or glycosylated haemoglobin (haemoglobin A1c, HbA1c, A1c, 
or Hb1c) is a form of haemoglobin that is measured primarily to identify the average 
plasma glucose concentration over prolonged periods of time. It is formed in a non-
enzymatic glycation pathway by haemoglobin’s exposure to plasma glucose. Normal 
levels of glucose produce a normal amount of glycated haemoglobin. As the average 
amount of plasma glucose increases, the fraction of glycated haemoglobin increases 
in a predictable way. There is not particular level for HbA1c to identify whether 
patients are or not at risk of type 2 diabetes as this is continuous risk factor. 
According to WHO recommendation the cut-off point of HbA1cfor diagnosing type 2 
diabetes in non-pregnant adults is a level of 48 mmol/mol (6.5%) and the range 42–
47 mmol/mol (6.0–6.4%) is considered to be 'high risk' (www.nice.org.uk) .This 
serves as a marker for average blood glucose levels over the previous months prior 
to the measurement (Miedema 2005; Peterson 1998). 
1.12 Treatment of Diabetes 
DM can be managed by diet, exercise and drug therapy. In terms of diet, more than 
50% of calorie intake should be from fibre-rich carbohydrates with minimal fat 
(especially saturated fat), refined carbohydrate and alcohol intake (Simon et al. 
2005). The total calorie intake for each individual should be adjusted according to 
their BMI to include a few portions of fresh fruit and vegetable in their daily diet; 
ready meals and alcohol should be avoided, as they are often sources of hidden 
sugar. In addition, regular exercise is encouraged as it can increase insulin 
sensitivity, decrease blood pressure and improve blood lipid control. 
In terms of drug therapy, there are two main types used to treat DM. 
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1.13 Pharmaceutical (synthetic) drug therapy 
The drug therapy for T1DM and for some patients with T2DM is insulin. Insulin 
therapy is a first-line treatment for T1DM whilst in T2DM it is considered only after 
diet and oral drug therapy have failed. Besides insulin, drugs currently used for 
T2DM treatment include sulfonylureas, biguanides and thiazides, followed by other 
medications like glitazon, ateglinide, repaglinide and acarbose (Royal 
Pharmaceutical Society 2015). The most widely prescribed medications for T2DM 
are sulfonylureas, which are derivatives of the antibacterial sulfonamides. Their 
mechanism of action is direct stimulation of the release of insulin from pancreatic 
beta cells, which leads to reduced blood glucose levels. This group of medications 
also decreases hepatic glucose production at higher doses. Second-generation 
sulfonylureas can have an additional pancreatic effects that result in increased 
insulin sensitivity (Briscoe et al. 2010; Basit et al. 2012).However, the mechanism of 
this effect is still unclear. 
Second-line treatments for T2DM start with biguanides, for example, metformin. The 
mechanism of metformin likely involves a peripheral insulin sensitisation, which 
corrects most of the major symptoms characterising insulin resistance syndrome, 
and increases glucose uptake in muscle. Metformin is able to reduce 
gluconeogenesis in the liver as well as decrease intestinal absorption of glucose. All 
these effects result in lower insulin resistance and better glycaemic control. On the 
negative side, the main side effect that has made these medicines potentially 
dangerous is the possible induction of lactic acidosis, especially if over-prescribed.  
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Also, many patients, especially elderly patients may be contra-indicated for 
metformin due to the risk of lactic acidosis (Scheen and Paquot 2013). 
Thiazolidinediones (glitazones or TZDs) are another class of drug for treating T2DM. 
The National Institute of Health and Clinical Excellence (NICE) guidelines 
recommend that TZDs could be used if diabetic patients cannot tolerate the 
combination therapy of metformin and sulfonylurea. The improvement of glucose and 
lipid metabolism is due to the agonist action of the PPAR gamma receptors, which 
increase transcription of certain insulin-sensitive genes, including those for 
lipoprotein lipase, the fatty acid transporter and the glucose transporter. Some 
examples of this class of drug are troglitazol, rosiglitazon and pioglitazon. On the 
negative side, this group of medications has several undesirable side effects, 
including inhibition of hepatic regeneration (Turmelle et al. 2006), induction of obesity 
(de Souza et al. 2001) and osteoporosis (Rzonca et al. 2004). Troglitazol was 
withdrawn from the market as a result of severe hepatotoxicity, unlike the 
aforementioned two drugs, which do not cause severe toxicity. 
Another line of treatment of T2DM is meglitinides, which include nateglidine and 
repaglidine. Their mechanism of action is similar to anti-diabetic sulfonylureas, but 
clearly they are in different categories. These drugs should be used in combination 
with metformin and are not applicable for T1DM. 
Glycoside inhibitors and glucagon like peptide-1 (GLP-1) are also used to treat 
T2DM. 
Although these and similar drugs have been used widely and have shown good 
results in management of DM, they are either expensive or can have undesirable 
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side effects, such as weight gain, oedema, anaemia and hepatotoxicity (especially 
with TZD), and furthermore, all of them fail to restore full glycaemic control 
(Balakrishnan et al. 2009; Laville and Andreelli, 2000). Thus, such side effects 
discourage the correct and complete observation of the medication protocol by some 
patients. On the basis of these drawbacks, it is highly desirable to find new anti-
diabetic compounds that increase the level of glucose uptake in different types of 
animal cells lines and do not have serious side effects like TZD (de Souza et al. 
2001; Laville and Andreelli 2000).  
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1.14 Herbal and complementary therapies 
Herbal medicine and plant derivatives have a long history of use as therapeutics for 
a variety of diseases and health conditions in many cultures around the world. There 
is an increasing trend in recent years towards the use of herbal-based therapeutics 
that originate from traditional medicines as an alternative or complementary 
treatment for some health conditions, such as hypertension, hyperglycaemia, 
hyperlipidaemia and cancer (Kim et al. 2011; Wazaify et al. 2013; Zhao et al. 2010; 
Ramkumar et al. 2008). There is also increasing interest in the field of herbal 
medicine research in investigating the efficacy and mechanisms of action of such 
derivatives. 
In past two decades considerable numbers of complementary medicines have 
become available through the National Health Service (NHS), but the accessability of 
those services however depends on the level of support and local interest 
(Zollman and Vickers 1999). About 1200 plants are used globally for the treatment of 
T2DM. However, only around 350 of them are registered as anti-diabetic agents 
(José et al. 2005). Such traditional methods of medical therapy have been widely 
and successfully used in some eastern countries, such as China, Egypt and Iran.  
It is well known that diabetes is one of the most disabling health conditions with 
increasing prevalence worldwide, which makes herbal derivatives with anti-diabetic 
properties increasingly attractive for further investigation. Studies on the effects of 
herbal derivatives on diabetes not only help us to identify new, active anti-diabetic 
molecules but may also provide us with better insight about the pathophysiology of 
diabetes. 
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 1.15 Moringaceae family 
A literature search for herbal derivatives with anti-diabetic effects highlighted 
Moringa peregrina as being relatively understudied. Its extracts have been 
suggested by some studies to have anti-diabetic effects (Ramkumar et al., 2008; 
Elbatran et al., 2005; Tsaknis 1998; Taha et al. 2011; Hanaa et al. 2013; Cederroth 
et al. 2009; Larijani et al. 2008), but active components had not been identified. The 
Moringaceae family is in the category of Brassicales or Capparales. There is only 
one genus recognised in this family, which is subdivided into 13 species, which can 
be found scattered around the tropical and semi tropical regions. All Moringa species 
originated mainly from India and from there they have found their way to many hot 
countries around the world. 
Members of this group are quite differentiated from each other in terms of 
characteristics such as morphology, habitat requirements and pharmaceutical 
applications. Some species, such as M. hildebrandtii, have become extinct in nature. 
Other species, such as M. arborea, are in danger of extinction.  
M. oleifera, the most common species of this group, is native to the Himalayan 
border regions and North West India, and can be found in many African countries, 
Arabian Peninsula, South East Asia, the Pacific Islands, the Caribbean and South 
America.  
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All known species of Moringa are listed below. 
1. M. arborea Verdcourt  
2. M. borziana Mattei  
3. M. concanensis Nimmo  
4. M. drouhardii Jumelle 
5. M. hildebrandtii Engler 
6. M. longituba Engler 
7. M. oleifera Lamarck  
8. M. ovalifolia  
9. M. peregrina Forssk. ex Fiori 1 
10. M. pygmaea Verdcourt  
11. M. rivae Chiovenda  
12. M. ruspoliana Engler 
13. M. stenopetala (Baker f.) Cufodonti 
In terms of structure evaluation, the genus Moringa is a class of dicotyledonous 
plants. The tree bears seed pods 20–40 cm long, each containing 8–15 unwigged 
seeds (Shojania et al., 2006). Young seeds of the plant are eaten in the way peas 
are eaten while mature seeds are fried or roasted like ground nuts. 
Moringa peregrina (Forssk.) Fiori, Agricolt. [Syn.; M. aptera Gaertn., M. arabica 
(Lam)], is also known as Ben-nut tree, Ben-oil tree, wild drumstick tree, and is the 
second most important type of Moringa after M. oleifera Lam. It is important in the 
food, pharmaceutical and environmental industries.  Its oil is used in the food 
industry due to the high content of mono-unsaturated fatty acids (like oleic acid), 
33 
 
which do not lose their quality when frying. In addition, the oil is used in 
pharmaceuticals, perfumes and even for streamlining parts in fine industries, such as 
watches or mobile laboratory devices that are only lubricated once in their lifetime to 
improve their resistance against heat and to avoid damage. 
There have been far more studies on the species of M. oleifera in comparison to M. 
peregrina. M. oleifera is rich in nutrients and proteins and has multiple 
pharmacological effects, its use in diabetes and abortion was described by Gupta 
and his colleagues (Gupta  et al. 2002),the crude ethanolic extract of its dry seed 
and hot water infusion of leaves, seed and roots of M. oleifera showed its  anti- 
inflamatoy and diuretic effect (Caceres et al.1992).Purification of ethanolic extract of 
the leaves gave different components namely,niazinin A and B, niazimicin , 
niaziminin A and B. These isolated compounds showed M.oleifera cardiovascular 
effect by exerting   hypotensive  and bradycardiac effect (Gilani et al. 1994).Other 
bioactive components were found from extract of this plant including  flavonoid group 
such as kaempferol and quercetin  and exerted the antioxidant properties  from 
phenolic constituents of M.oleifera (Siddhuraju et al 2003). 
The leaves of this plant are a rich source of beta-carotene, protein, vitamin C, 
calcium and potassium. The plant is a natural source of antioxidant used to store 
high-fat foods. M. oleifera is a fast-growing species in tropical and subtropical areas, 
with extensive growth in Asian countries. This type of Moringa species is the only 
species that is cultivated intensively for commercial use in some countries. Because 
of its numerous uses of the plant, this species is also known as the miracle plant 
(Ashfaq et al. 2012). 
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          Figure 1.7 Moringa peregrina plant 
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1.16 Phytoestrogens 
Phytoestrogens are a group of chemicals that naturally occur in plants with 
oestrogenic properties allow them to act as agonists and antagonists of oestrogen 
(Yildiz, 2005). The pharmacological effects are mediated through binding to 
oestrogen receptors. There are two types of oestrogen receptors in the human body, 
ER alpha and ER beta and phytoestrogens have higher affinity for ER beta than for 
ER-alpha (Turner, 2007). Phytoestrogens were first synthesised by Baker and 
Robinson in 1928 (Walter E. D. 1941), after which isoflavones, which is a group of 
phytoestrogens, were found in soybean meal (Soja hispida) by Waltz (Al-Othman et 
al., 1998). Another group of phytoestrogens called lignans were discovered by 
Haworth in 1941 (Marwah, 2006).  Several studies were carry out to assess the  
reproductive effect of phytoestrogens particulary isoflavones (Bennetts et al.1946, 
Carter et al. 1955 and 1960 East J. 1955). Following these investigations, 
pharmacokinetic studies were carried out on animals as well as humans (Cederroth 
et al. 2009; Oergaard et al. 2008; Hintz et al. 2004; Bhathena et al. 2002; 
Stephenson et al. 2002; Jayagopal et al., 2002; Hepburn et al. 2002; Tourandokht et 
al. 2008; Sun et al. 2006; Hasani-Ranjbar et al. 2008; Shen et al. 2006; Santti et al. 
1998; Curran et al. 2004; Harris et al. 2005; Zhou et al. 2009). Subsequently, the 
effects of phytoestrogens and their metabolites on estrogen receptors (ER) have 
been recognised and their estrogenic and anti-estrogenic activities confirmed, as 
well as their high affinity for uterine estrogenic receptors (Turner et al. 2007). 
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1.17 Classification of phytoestrogens 
Phytoestrogens can be categorised into two main categories depending on their 
strutctures; the flavonoids and non-flavonoids as described in Figure 1.8. The 
isoflavones and coumestans from the flavonoids class have the highest estrogenic 
activity. Prenyl flavonoids are another member of this group that have been 
discovered recently and have not yet been fully investigated. In the non-flavonoids 
class of phytoestrogens, lignans have been well studied and have potent estrogenic 
activity, followed by stilbenes, which include the widely studied resveratrol. 
 
Fig.1.8. General classification and examples of phytoestrogens (adapted from Yildiz 2005, Sriraman et al. 
2015, Brown et al. 2014, Touillaud et al. 2005 Nut) 
 
 
phytoestrogens 
flavonids 
Isoflavones 
e.g daidzein 
coumestans 
e.g coumestrol 
Prenylflavonoids 
e.g 8- 
prenylnaringenin 
sterols 
e.g 
ȕ-sitosterol 
Non-flavonoids 
Lignans 
e.g 
secoisolariciresinol 
Stilbenes 
e.g resveratrol 
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                     Daidzein                                                        Genistein 
 
                         
                          Coumestrol                                                         Formononetin 
 
 
  
                             
      8-Prenylnaringenin (8-PN)                                         Secoisolariciresinol 
 
      
                                      
             Resveratrol                                                         ȕ-sitosterol 
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1.18 Aim of the work  
This project aimed to investigate the anti-diabetic properties of M.Peregrina and 
phytoestrogens by in-vitro techniques, with a view to characterising new phyto-
preparations with anti-diabetic properties. HepG2 cells were chosen for assaying 
glucose uptake, consumption and metabolism sterols.  
The strategy was to prepare a series of extracts of M.peregrina leaves using 
solvents with a range of polarities. These would be screened for potential anti-
diabetic activity to identify the most active fractions. The active fractions would 
undergo rigorous further extraction and analysis to identify individual phyto 
components, which could be assayed individually for anti-diabetic activity. 
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Part I 
Preparation and purification 
Of 
Moringa peregrina extracts 
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2.1 Preparation of Extracts of M.peregrina  
 
In this part of the work there were two phases of preparation of extracts. One at the 
beginning of the work involving preparation of crude extracts for screening, and the 
second involving purification of isolated phytochemicals from the most active extract. 
The first phase was done at the Institute of Medicinal Plants in the city of Karaj, Iran, 
and the second phase was done at the University of Tarbiat Modares and Shahid 
Beheshti in Tehran, Iran. 
 
2.1.1 Plant sources  
 
Plant sources used in this project include aerial parts of M.peregrina that were 
collected from the province of Sistan-Baluchestan, city of Nikshahr in Iran, from a 
height of 300 meters above sea level in June 2010. This plant was previously 
registered in the Herbarium of Medicinal Plants in Karaj, Iran, with the registration 
number ACECR-44. 
 
2.1.2 Chemicals 
 
2,2-Diphenyl-1-picrylhydrazyl (DPPH), beta-carotene and sodium carbonate were of 
analytical grade from FLUKA . Methanol, ethanol, dimethyl sulfoxide (DMSO) and 
other solvents, Folin reagent, Tween 40, linoleic acid, and butylated hydroxytoluene 
(BHT) were obtained from Merck . 
 2.1.3 Extraction and preparation of fractions  
Dried aerial parts of M. peregrina (1kg) were extracted by successive percolation 
with solvents of increasing polarity at room temperature, starting with n-hexane. The 
extract then was concentrated using smooth finish paper and rotary evaporator and 
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dried in a Petri dish. Chloroform were added on the remaining amount of plant and 
extracted. After extraction with chloroform the remaining plant was dried in the dark 
and then extracted with ethanol 70% (each extract three times with 500 mL of 
solvent, for 24 hours). The ethanol extract was concentrated, suspended in water, 
and successively partitioned with EtOAc and n-butanol. The n-hexane extract (Hxe), 
chloroform extract, and ethyl acetate and n-butanol fractions (Btf) were obtained, 
along with the water fraction (Wtf). All extracts were filtered out, dried with a vacuum 
using a rotary evaporator, and brown viscous residues were obtained and stored in 
the dark at 4ºC prior to use, the extraction lasted 7 to 10 days. 
Following the in vitro study in this project, positive biological activity was found in 
extracts of ethyl acetate and chloroform and further phytochemical investigation on 
these two active extracts were performed.  
 
 
  
 
 
3. Purification of the active compounds of ethyl acetate and 
chloroform extracts 
 
The extracts were purified by using silica gel chromatography (250g and 220g) with 
grade 60 silica gel (0.063-0.200mm, 70-230 mesh), column length 90 cm, internal 
diameter (i.d) 3.5 cm. Compounds were separated and monitored by thin layer 
chromatography (TLC) followed by preparative High Performance Liquid 
Chromatography. Proton nuclear magnetic resonance (1H NMR) and carbon-13 
nuclear magnetic resonance (13C-NMR) were used for determination of compound 
structures. 
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NMR spectra were recorded at a target temperature of 18 °C on a Bruker Avance III 
500 MHz spectrometer operating at 500.13 MHz for 1H and 125.77 MHz for 13C. A 
1-mm TXI microprobe with a z-gradient was used for 1 H-detected experiments. 
13C-NMR spectra were recorded with a 5-mm BBO probe head with z-gradient. 
Spectra were analyzed using Bruker TopSpin 2.1 software. Analytical HPLC 
separations were performed with a Knauer HPLC apparatus consisting of a 1000 
Smartline pump, a 5000 Smartline manager solvent organizer, and a 2800 Smartline 
PDA detector. Injection was performed through a 3900 Smartline autosampler 
injector equipped with a 100 µL loop. Temperature control of the column was with a 
Jet Stream 2 Plus oven (Knauer, advanced scientific instrument). Data acquisition 
and integration was performed with EZchrome Elite software. The flow rate of the 
mobile phase was kept at 1.0 mL/min. Preparative HPLC was done on a Knauer 
Wellchrom series consisting of K-1800 pump, UV detector k-2501, and a Büchi 
fraction collector (Büchi Labortechnik AG). Knauer Eurospher 100-5 C18 (250 
mm×4.6 mm, 5 µm), and Eurospher-100 (120×16 mm, 5 µm) HPLC columns with 
precolumn were used for analytical and preparative separations, respectively. 
High resolution mass spectra(MS) was used , the samples was analysis with 
micrOTOF ( bruker) , where Electrospray ionization and Time of flight (TOF) was 
used. .For Isolation of constituents from the EtOAc extract ,the column was eluted 
with a gradient of ethyl acetate/methanol (100:0  0:100). Fractions of 20 mL were 
collected and monitored by TLC (silica gel 60 F254, Merck, ethyl acetate 100%; 
detection with H2SO4 3% reagent and heating) and eight fractions were obtained. 
In the procees Isolation of constituents from the chloroform extract, the column was 
eluted with a gradient hexane/ethyl acetate (100:0  0:100) and followed by ethyl 
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acetate/methanol (100:0  80:20). Fractions of 20 mL were collected and monitored 
by TLC (silica gel 60 F254, Merck, detection with H2SO4 3% reagent and heating). By 
adding the  fractions  with the same solvent  and evaporating them at the end 15 
fractions were obtained. 
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Part II 
In vitro studies on glucose uptake 
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4.1 Introduction   
Stimulation of glucose uptake is a key parameter of the hypoglycaemic effect of 
known anti-diabetic drugs (Kawamori et al.1995; Yu et al. 2015).  
To establish the hypoglycaemic effect of the compounds in this part of the work two 
methods of study was designed for measurement of glucose metabolism in HepG2 
cells, measurement of glucose uptake and measurement of glucose consumption.  
This part of the project was performed in the Research Laboratory of London 
Metropolitan University.  
 
  
4.2 Materials 
HepG2 cells were obtained from King’s College Medical School Liver Unit.  DMEM 
(Dulbecco's Modified Eagle Medium) glucose free and with glucose, methanol, 
dimethyl sulfoxide (DMSO), Costar 24 well plates, 2-(N-(7-nitrobenz-2-oxa-1, 3- 
diazol-4-yl) amino)-2-deoxyglucose (2-NBDG) were obtained from Sigma Aldrich 
(Poole, Dorset, UK). 
 
 
4.3  Cell culture 
4.3.1. HepG2 cell line 
The cell line HepG2 is a human liver carcinoma cell line. This is a  perpetual cell line 
and have an epithelial morphology with stable chromosome number of 54 with 
variation between 54 to 56 in 90% of the cells ( Simon et al.1982). HepG2 cells 
exhibit most cellular characters of normal human hepatocytes and produce a wide  
range of valuable biochemical molecules from proteins groups including albumin, 
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iron-binding blood plasma glycoprotein transferrin, glycoproteins such as fibrinogen, 
high molecular weight plasma proteins like α2-macroglobulin, protease inhibitors 
(Alpha-1 antitrypsin) and plasmin which is degradation enzyme for blood plasma 
protein such as fibrin clots. 
4.3.2. Cell Culture 
The human hepatoma HepG2 cell line was used in this work, and was grown in 
DMEM with 11 mM glucose (Gibco) and 10% foetal calf serum. Glucose was added 
to 11 mM for most experiments unless otherwise stated. HepG2 cell cultures were 
started from frozen cells, using standard protocols (Hanaa et al.2011). A vial of cells 
was collected from liquid nitrogen storage and the lower half submerged in a water 
bath at 37 °C. After allowing to thaw until a small amount of ice remained in the vial 
(usually 1-2 minutes), the vial was transferred to a sterile safety cabinet. The vial 
was wiped with a tissue moistened with 70% alcohol, the cap removed and the cells 
were removed by slow pipetting to pre-warmed growth medium. The cells were 
centrifuged at 1000 rpm at room temperature for 5 minutes to remove the DMSO in 
the cryopreservation medium. The medium was carefully removed and replaced with 
new medium and the cells slowly pipetted to a flask. Cells were grown at 37 °C in 5% 
CO2 / air. 
The HepG2 cell line is anchorage dependent and must be cultured while attached to 
a solid or semi-solid substrate (adherent or monolayer culture). The fibroblastic 
morphology of the cells was examined by microscopy at each sub-culture. An 
example is shown in Figure 2.1   
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Figure 2.1.  Fibroblastic morphology of HepG2 cells.  
Fibroblastic (or fibroblast-like) cells are bipolar or multipolar, have elongated shapes, and grow 
attached to substrate.  The image shows a reverse-phase microscopy picture of HepG2 cells taken 
during my PhD project. A scale bar of 100 m is shown. 
 
 
4.3.3. Subculture of HepG2 cells  
When a flask of cells was at, or near confluency, the culture confluency as well as 
absence of bacterial and fungal contamination were checked by microscopy. Spent 
medium was removed, cells were washed with a half volume of culture medium. 
Trypsin-EDTA (1ml per 25 cm2 of surface area) added to the flask, washed over the 
cells, then the flask was returned to the incubator and incubated until cells detached.  
The cells were examined by microscopy to ensure that they were fully detached and 
floating, then a small volume of the fresh serum-containing medium was added to 
inactivate the trypsin (Elbatran et al. 2005; Ramkumar et al. 2008). Cells were 
seeded into a fresh flask at a concentration of approximately 0.5x105 in 5 mL 
medium per 25 cm2 flask area. Viable cells were counted by trypan blue exclusion 
using a haemocytometer. 
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 4.3.4 Glucose uptake in HepG2 cells 
For in vitro glucose uptake assays using 2-NBDG, it was important to optimize the 
conditions of uptake of 2-NBDG by HepG2. 2-NBDG is a fluorescent derivative of 
glucose modified with a 2-[N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino group at the 
C-2 position (Molecular Weight = 342.26) (Yoshioka 1996).  The probe shows 
intense fluorescence at 542 nm when excited at 467 nm. 5mg 2-NBDG was 
dissolved in 1.46 mL of methanol in order to make a 10mM as a stock solution. 5 
mM, 1 mM, 0.5 mM and 0.1mM solutions were prepared in methanol, as shown in 
Table 2.1. Methanol only was used as a vehicle control.  
. 
Final concentration 
of 2-NBDG (mM) 
Stock/Vol. Vol MeOH 
5 10mM/100 µL 100µL 
1 5mM/40 µL 160 µL 
0.5 1mM/100 µL 100 µL 
0.1 0.5Mm/40 µL 160 µL 
Table2.1 Dilutions of 2NBDG used for optimising the uptake assay. 
 
  
HepG2 cells were sub-cultured using DMEM medium with glucose, 10mL of medium 
was added and cells were transferred into flasks, cells were seeded at a density 5.0 
x104 cells per mL and incubated with 10 mL of medium. Cells were counted using a 
haemocytometer and diluted to 0.5x105 cells/mL. Then the cells were aliquotted at 
0.5 mL per well in a 24-well plate and incubated for 24 hours. 5 µL of 0, 0.1, 0.5, 1, 5, 
or 10 mM 2-NBDG , was added to columns one to six respectively (from right to left), 
so that the 2-NBDG was diluted 100 times. Cells were incubated at 37 °C for 15 
minutes then washed with PBS and fluorescent uptake was measured using an 
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Omega FluoStar (BMG LabTech, Ayelsbury, Bucks, UK) plate reader with ex = 
485nm, em = 530nm, using the bottom optic and a gain of 1000. 
Various modifications of the procedure were tried. One involved replacing normal 
medium with glucose-free medium after 24 hours. Another concern was the optimal 
period of incubation with 2-NBDG, and uptake was accordingly monitored from 15 
minutes to 2 hours. The glucose uptake increase was checked by fluorescence 
microscopy. 
 
4.3.5. Glucose uptake measurement after treatments 
Preliminary experiments for testing the effect of extracts of M. peregrina, known anti-
diabetic drugs and phytoestrogens on glucose uptake were carried out to test the 
influence of Incubation time, cell density and growth phase, concentration of 2-
NBDG and plate-reader parameters for measuring fluorescence.  These are 
described in the Results section. 
According to previous studies the concentration of crude plant extracts used in cell 
culture experiments was in the range of 10 mg/mL to 20mg/mL, and was used as a 
reference for the current study (Mekonnen et al. 2005;Jung et al. 2015 ;Haasan et al. 
1995, O’Neil  et al. 2005). 
10mg of dry extract was dissolved in 1.0 mL of DMSO to prepare a stock solution. 
HepG2 cells were cultured using various concentrations of cells in a 24-well plate 
and grown for 24 hours.  After 24 hours the medium was replaced by 0.5 mL of 
DMEM glucose-free medium, supplemented with 5 µL of M. peregrina extracts  
prepared with hexane, chloroform, ethyl acetate, N-butanol, water and methanol and 
dissolved in DMSO at a concentration of 10 mg/mL. Three wells per plate were used 
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for each extract and three wells per plate received 5 L DMSO only as vehicle 
control. Three wells were left without any treatment as a further negative control. 
Cells were treated for one hour (short-term treatment) or 24 hours (long-term 
treatment). 2-NBDG was added and cells incubated for 15 min, after which glucose 
uptake was measured as described above. 
In one modification cells were cultured for 24 hours and treated with the extracts for 
24 hours. After the incubation time medium replaced with glucose free medium. 
Then 2-NBDG added and incubated for 15 minutes after which the glucose uptake 
was measured by the fluorescent reader (Omega FluoStar plate reader). 
 
4.3.6. Comparison of short term and long term treatment of three active 
extracts of M.peregrina (hexane, CHCl3, EtOAc) on glucose uptake in confluent 
HepG2 cells. 
The objective of this part of the project was to further study the effect of the three 
active extracts of M.Peregrina on regulating glucose uptake in-vitro. 
HepGβ cells were seeded at 0.5x105 cells/mL, and allowed to grow overnight. The 
next day cells were treated with 50 g of hexane, CHClγ and EtOAc extracts and 
incubated for one hour as a short-term treatment, or β4 hours as a long-term 
treatment.  At the end of the treatments normal DMEM medium was replaced by 0.5 
mL glucose free medium, then 5 L of 10 mM was β-NBDG added into three wells in 
each row in order to have γ wells as a control. After incubating for 15 minutes, the 
cells washed with PBS and fluorescent intensity measured.  
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4.3.7. Comparison of Glucose uptake effect of known anti-diabetic drugs with 
the three active extracts of M.Peregrina. 
The aim of this part of the work is to compare the effect of the active extracts on 
glucose uptake with known anti-diabetic compounds such as metformin (Sahra et al. 
2008), berberin (Yin et al. 2008; Yina et al. 2012) and ouabian (Reid et al.1996), as 
well as with a known inhibitor of glucose uptake, phloretin. 
The cell culture, treatments and measurement methods were performed as 
described in section 2.4. 
 
4.3.8. Glucose uptake measurement after treating confluent HepG2 cells with 
three phytoestrogens. 
This part of the project was started by making serial dilutions of three phytoestrogens 
genestein, daidzein and formononetin (Sigma Aldrich, UK). Stock solutions of 10 
mM, 1 mM, 100 M, 10 M, 1 M, and 0.1M were prepared in DMSO.  HepG2 cells 
were cultured and treated as described in section 2.4.  
 
5. Glucose consumption 
A glucometer is a medical device for measurement of glucose levels in blood. 
However it can be used for research purposes in the laboratory as well, and was 
used in this study to measure changes in the levels of glucose in cell culture 
medium.  The SD Codefree device used in this study is made by SD Biosensor Inc, 
Korea (Home Health UK, Watford, Herts) and uses a glucose oxidase biosensor with 
a measurement range of 0.6 ~ 33.3 mM.  Each strip needs 0.9 µl of liquid sample for 
a single accurate measurement.   The test strip was inserted into the device and the 
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surface of the cell culture medium was touched by the end of the strip, to receive a 
small volume of medium by capillary action.  
The accuracy and reliability of glucose measurements using the SD Codefree 
glucometer was tested to establish the reading error rate. Cell culture medium with 
glucose concentrations of 1.6, 3.12, 6.25 and 12.5 mM were prepared by adding 
appropriate amounts from a 2.5 M stock solution (Sigma-Aldrich).  Each medium was 
measured ten times with ten strips and the average readings are shown in Table 1.1.  
It was estimated that the glucometer shows the glucose concentration in cell culture 
medium with a value 7% to 10% above actual glucose concentration, over the range 
1.6mM to 12.5 mM (Table 2.2).  
 
 
 Actual         
Concentration 
(mM) 
Glucometer     
reading 
(mM) 
% of error SD 
Solution 1 12.5 13.5 +8 0.12 
Solution 2 6.25 6.75 +8 0.03 
Solution 3 3.12 3.33 +7 0.06 
Solution 4 1.6 1.72 +7.5 0.04 
 
Table 2.2 Comparison of actual glucose concentration with the reading from glucometer (average of ten 
readings). The average of the error is 7.6%. This percentage correction was deducted from values recorded 
experimentally. 
 
5.1. Treatment of HepG2 cells with active M. peregrina extracts 
The effects of the extracts of M. peregrina on HepG2 cells were assessed after two 
hours, 24 hours and 48 hours treatment, and were compared with a known anti-
diabetic drug, metformin, that acts by promoting glucose uptake in peripheral tissues. 
24 hours after seeding HepG2 cells into a 24-well plate, as described above, the 
medium of each well was removed and replaced with 0.5 mL fresh full DMEM 
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medium with a glucose concentration of 11mM.  Cells were treated with the two most 
active extracts of M. peregrina found in previous work to enhance glucose uptake 
into HepG2 cells, described briefly in the Results section. 5L of extract (10mg/mL) 
in DMSO were added to three replicate wells in each experiment.  In addition one set 
of wells received 5L of DMSO only as vehicle control. One set of wells received 
10L of 1mM metformin in DMSO (Sahra 2008). The remaining wells of the plate 
were assayed as negative controls with no treatment.   
 
5.2. Calculation of glucose consumption per cell 
HepG2 cells were grown to more than 80% confluency and then the medium 
replaced by fresh medium containing 11 mM glucose and treatments at the same 
time. Glucose consumption by HepG2 cells was calculated by deducting the levels of 
glucose in the cell culture medium after incubation period (2, 24 and 48 hours in 
separate experiments) from 11mM as the amount of glucose in zero time. The 
glucose values were adjusted, based on 7.6% error rate. The medium was removed 
from the wells immediately after glucose measurements and replaced with 100L 
trypsin solution, then kept in the incubator for 3-5 minutes.  400L of medium was 
added to each well after cells were detached and cell counting was carried out using 
a haemocytometer. The glucose consumption in each group was normalised using 
cell count to eliminate the bias due to variation in cell number as much as possible.  
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6. Analysis of GLUT1 expression by western blotting 
 
6.1 Preparation of cell lysates 
Cell lysates were prepared for western blotting. Treated HepG2 cells were washed 
once with EDTA-PBS (phosphate buffered saline with concentration of137 mM NaCl, 
10 mM phosphate, 2.7 mM KCl , pH 7.35,  with EDTA, 2 mM), 5.0 mL trypsin 
solution added, and the flask incubated at 37 °C. Under these conditions HepG2 
cells detached easily without the need to use a scraper. 5.0 mL full medium was 
added to the flask and cells were transferred to a 15 mL tube and spun 5 min. at 800 
rpm, 4 °C; the cells collected as a pellet.  The medium was removed carefully and 
the cells washed once with 5.0 mL ice-cold PBS, then collected by centrifugation as 
in the previous step. 1.0 mL of ice-cold PBS was added to the pellet and the re-
suspended cells were transferred to a 1.5 mL microfuge tube; then the cells were 
collected by spinning for 10 seconds at 5000 rpm. The PBS was carefully removed 
and one volume (with respect to the cell pellet) of ice-cold RIPA buffer with protease 
inhibitor cocktail This mixture contains individual components, including AEBSF at 
104 mM, Aprotinin at 80 μM, Bestatin at 4 mM, E-64 at 1.4 mM, Leupeptin at 2 mM 
and Pepstatin A at 1.5 mM (Sigma Aldrich, UK),  was added then gently pipetted up 
and down to mix the cells thoroughly and left on ice for 5 min. The extract was spun  
at 12,000 rpm for 5 min at 4 °C; the supernatant, containing solubilised plasma 
membranes and cytosolic proteins, was stored  at -20 oC.The soluble extracts 
(supernatants) were analysed by Western Blotting.  
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6.2.  Western blotting 
The procedure of this experiment followed a standard protocol; a shortened version 
is given here. 
6.3. SDS Polyacrylamide Gel Electrophoresis 
1-1 Preparation of the Running and Stacking Gels 
A very clean and dry glass plate, an aluminium backing plate and two spacers (0.75 
mm) are assembled into a Vertical Slab Gel and placed into a gel caster carefully to 
prevent leaks and water added to test for leaks. 
The running gel solution (RGS) containing 10% acrylamide was prepared in a plastic 
tube, TEMED (N,N,N′,N′-Tetramethylethylenediamine 
colorless liquid and soluble in water, methanol and aceton ) and APS (Ammonium 
persulfate soluble in water (100 mg/ml), yielding a clear, colorless solution)added 
last (APS and TEMED are catalysts for polymerization of acrylamide) A volume of 
RGS was pipetted into the vertical gel caster to a level that left 1 cm to the teeth of 
the comb, to give enough space for the stacking gel. 
A volume of water saturated with n-butanol solution was added on the top of the 
running gel to prevent the possible reaction between the gel solution and the 
atmospheric oxygen and the RGS was left for 20-30 min at room temperature to 
polymerise. The n-butanol was removed from the gel. The stacking gel solution 
(SGS) was prepared and TEMED and APS added last. Then a comb inserted and 
the SGS is pipetted into the space at the top of the aluminium and was left for 20 min 
to polymerise. 
1.2 Sample preparation: 
One volume of sample was added to one volume sample buffer and heated at  
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95 °C for 5 min to denature the proteins; the sample was allowed to cool before 
loading.  Denatured samples were stored at –β0 °C for long term storage.  Loadings 
were typically 10 or β0 L per well. 
1.3 Loading Samples onto the Gel Apparatus 
The gel unit (glass and aluminium plates and spacers in the cassette) was placed 
into the electrophoresis tank containing running buffer. Buffer poured into the 
cassette chamber and the comb was slowly removed from the stacking gel. 
The same volume, β0 L, of chloroform and ethyl acetate extract treated samples 
and controls were loaded into the wells; 5 L of BioRad markers were used. 
1.4 Running the Gel 
The stacking gel was run at 10mA and the power increased to 20mA after the 
samples moved into the running gel, constant current (power supply, POWER PAC 
300, BioRad).  
 
6.4. Blotting 
The aluminium plate and the gel (still united) was submerged in Towbin Transfer 
Buffer (TTB) with composition of 3.03g Tris-base, 14.41g Glycine, 10 mL 10% 
SDS,up to 800 mL with H2O, 200 mL  methanol , for  5 – 10 min. Then the stacking 
gel removed and the running gel separated from the plastic plate. Four pieces of 
blotter paper (Whatman, 3MM), the same size as the sponges for the blot, and one 
piece of nitrocellulose membrane were cut (e.g. Hybond – C extra, Amersham). All 
the papers, the sponges and the membrane were wetted with TTB. 
 
58 
 
The order for the contents of the transfer cassette (“sandwich”): 
1- grey side of the cassette  
2- sponge 
3- two pieces of blotter paper 
4- membrane 
5- running gel 
6- two pieces of blotter paper 
7- sponge 
8- black side of the cassette 
The cassette was closed and inserted into the transfer apparatus (TE22, Hoefer 
Scientific Instruments), the grey side with the positive pole (anode). The proteins go 
from the gel (- side) to the membrane (+ side). Proteins transferred overnight at room 
temperature with a constant voltage of 10V. 
 
6.5. Immunodetection of a GLUT1 
After transfer of proteins the membrane was washed with TBS for 5 – 10 min and 
loose acrylamide removed. Then the TBS is removed and molecular weight markers 
were marked on the membrane with an indelible ink pen. Blocking Buffer (3 % w/v 
“Marvel” milk powder in TTBS) was added and the membrane incubated on a shaker 
(4RT Rocking Table, LuckHam) at room temperature for at least 30 min. The 
blocking buffer was discarded and the membrane washed three times in wash buffer. 
The wash buffer was poured off and the membrane incubated with the primary 
antibody solution, GLUT1- antibody (C-terminal) is produced in rabbit using as 
immunogen and categorically recognise rat GLUT1. The antibody can be used in 
numbers of immunochemical techniques such as immunoblotting (55-70 kDa).       
The membrane was incubated with constant shaking at room temperature for at least 
2 hours. Then the primary antibody solution is discarded and the membrane is 
washed three times for 5 min in wash buffer. The wash buffer is poured off and the 
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membrane incubated with the secondary antibody solution (usually a 1:1000 dilution) 
– for example an anti-rabbit IgG labelled with horse-radish peroxidase (HRP). The 
membrane was incubated on a shaker at room temperature for at least one hour.  
  
6.6. Incubation with the substrate (for horse-radish peroxidase) 
The membrane was washed five times in wash buffer. After this the membrane was 
placed into a plastic sleeve sealed at the bottom with the top open.  2 to 4 mL 
luminescent substrate solution was freshly prepared according to the manufacturer’s 
instructions, and pipetted into the sleeve over the membrane, the volume depending 
on the size of membrane. It was kept in the dark for two minutes, the solution poured 
off / squeezed out, and fresh solution added.  The membrane was incubated for two 
minutes in the dark, the excess liquid poured off, leaving the membrane moist.  The 
moist membrane was placed into a plastic sleeve for image analysis using a UVitec 
(Cambridge, UK) documentation system. The intensity of each band in the blot is 
measured using image J software and the intensity of bands compared for analysis.  
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Part III 
Studies on cell metabolism 
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7.1 Cell metabolism and mitochondrial respiration analysis 
The Seahorse Bioscience (Massachusetts, US) XF24 machine was designed to test 
mitochondrial function of cells in real time, with high throughput and as an alternative 
to using a much more labour intensive and low throughput, but well-established 
methodology using the classical oxygen electrode. 
The XF cell Mito stress Kit was developed to assess mitochondrial function on the 
basis of the rate of change of dissolved oxygen and pH in the media immediately 
surrounding living attached cells cultured in a microplate in real time mode. This 
provides an accurate measurement of the rate of cellular metabolism in detail.  
Exclusive factors in the technology of the XF include calculation of oxygen and 
proton exchange rate based on short periods (5 minutes) of measurement, achieved 
with a small volume of medium.  
The apparatus uses 24 optical fluorescent heads fixed in sterile disposable 
cartridges which locate into a 24 well tissue culture microplate. Each head becomes 
immersed in the medium of each well and can transmit optical signals independently, 
and simultaneously, with the other heads. The test runs every 2-5 minutes 
approximately and generates the data for oxygen consumption rate (OCR) in 
pmol/min which shows mitochondrial respiration, and extracellular acidification rate 
(ECAR) in mpH/min that is due to glycolysis. The experiment was performed at the 
University of Westminster.  
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Figure 3.1 | XF Cell Mito Stress Test. Profile of the key parameters of mitochondrial respiration. Sequential 
compound injections measure basal respiration, ATP production, proton leak, maximal respiration, spare 
respiratory capacity, and non-mitochondrial respiration.(Adopted from www.Seahorsebio.com) 
 
Three respiration modulators are used in the XF Cell mito stress test. Each 
modulator works on a specific target complex of the electron transport chain (ETC). 
Oligomycin is used first, and inhibits ATP synthase (complex V) and thereby 
decreases the oxygen consumption rate (OCR) by mitochondrial respiration, which is 
directly linked to cellular ATP production. The uncoupling modulator, carbonyl 
cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) uncouples the mitochondrial 
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membrane potential and destroys the proton gradient across the membrane. This 
means respiration is nolonger linked to production of ATP and electron discharge via 
the ETC is only limited by oxygen availability and complex IV oxygen consumption is 
at a maximal level. The third agent is a combination of rotenone, a complex I 
inhibitor, and antimycin A, a complex Ill inhibitor. This mix completely inhibits 
mitochondrial respiration allows measurement of non-mitochondrial respiration 
induced by processes outside the mitochondria. 
The cell’s ability to react to increased energy demand is called spare respiratory 
capacity, and can be calculated from the difference between maximal respiration and 
basal respiration. This can be calculated by using the FCCP-stimulated OCR (Figure 
3.2, Table 2.3).  
 
 
Figure 3.2| XF Cell Mito Stress Test Modulators of the ETC. This diagram illustrates the 
complexes of the ETC and the target of action of all of the compounds in the XF Cell Mito Stress Test 
Kit. Oligomycin inhibits ATP synthase (complex V), FCCP uncouples oxygen consumption from ATP 
production, and rotenone/ antimycin A inhibit complexes I and Ill, respectively.(Adopted from 
www.Seahorsebio.com) 
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7.1.1 Materials  
Uridine, penicillin/streptomycin, DMEM, glucose, glutamine, sodium pyruvate, 
buffering agent  and HEPES were from Sigma-Aldrich; trypsin was from Invitrogen 
and fetal bovine serum from Hyclone.  Other consumables were from Seahorse 
Bioscience (XF24-3 FluxPak cat. No. 102070-001; XF Cell Mito Stress Test Kit cat. 
No. 101706-100.  
7.1.2 Cell culture and Treatments: Cells were maintained in DMEM, 10% FBS + 22 
mM glucose, in 75-cm2 T-flasks in a controlled incubator at 37°C, 95% humidity, and 
10% CO2. Every two to three days, HepG2 cultures were detached from the flasks 
using a 0.25% solution of trypsin and subcultured. All cultures were maintained at 
less than 80% confluence at the time of subculture. For XF24 assays, cells were 
seeded at 30,000 cells/well in an XF24 cell culture microplate. 
Cells were incubated with treatments including control, 8µM (O-ethyl 4-[(α-L-
rhamnosyloxy) benzyl] thiocarbamate (E))   (MA4Pβ), γ0 µM ȕ- sitosterol, and 10 µM 
rutin ( M8P2) for two hours before the start of the experiment (Figure 3.3, Figure 
3.4). 
Basal respiration in the presence of the treatments, proton leak and ATP turnover by 
adding oligomycin (10μM) to inhibit ATP synthesis, maximal mitochondrial 
respiratory capacity by adding FCCP (carbonyl cyanide 4-trifluoromethoxy 
phenylhydrazone) (10μM) as uncoupler, and non-mitochondrial respiration by adding 
rotenone and antimycine (5μM) to stop mitochondrial respiration were measured as 
OCR. Protein extraction was carried out for each well at the end of the experiment. 
OCR readings were normalized to total protein per well which was measured using a 
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Pierce BCA Protein Assay Kit (ThermoFisher Scientific, UK), with triplicate samples 
assayed per well. 
 
 
Background Control Control Control Control Control 
O-ethyl 4-[(α-L-
rhamnosyloxy) 
benzyl] 
thiocarbamate 
(E) 
O-ethyl 4-[(α-L-
rhamnosyloxy) 
benzyl] 
thiocarbamate 
(E) 
O-ethyl 4-[(α-L-
rhamnosyloxy) 
benzyl] 
thiocarbamate 
(E) 
Background O-ethyl 4-[(α-L-
rhamnosyloxy) 
benzyl] 
thiocarbamate 
(E) 
O-ethyl 4-[(α-L-
rhamnosyloxy) 
benzyl] 
thiocarbamate 
(E) 
beta-sit beta-sit Background beta-sit beta-sit beta-sit 
rutin rutin rutin rutin rutin Background 
 
Figure 3.3 Seahorse assay plate layout. The layout of the three chosen compounds in the seahorse 24-well 
microplate 
 
               
-  
Figure 3.4 Plan of the plate used in the Seahorse experiment according to the 
layout in Figure 3.3,the colours are indicate the treatment in each well; blue is for 
control, black shows  backgrounds , green is for 
O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate (E),yellow is for ȕ-sitosterol 
and purple is for rutin 
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Chapter III 
Characterisation of Phytochemicals from 
Extracts of M.peregrina 
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8.1 Introduction  
The in vitro study of M.peregrina extracts in this work revealed that the ethyl acetate 
and chloroform extracts have the most hypoglycemic effect on HepG2 cells among 
the six extracts. A phytochemical analysis process was designed for the purification 
and characterization of components from these two active extracts. 
Essential oil purification for M.peregrina from its seed and leaves for first time 
showed that the majority of components are isobutyl isothiocyanate and isopropyl 
isothiocyanate (Afsharypuor et al. 2010), and further studies on the volatile 
constituents of the seed coat and stem of M.peregrina also reported isobutyl 
isothiocyanate as a main component (Dehshahri et al. 2012). Another study on 
M.peregrina assessed levels of glucosinolates in leaves (Bellostas et al. 2010). 
Characterisation of M.peregrina extracts described in the latest studies identified a 
number of components including, ȕ-sitosterol , ȕ-sitosterol-3-O-glucoside, quercetin, 
quercetin-3-O-rutinoside, ȕ-amyrin, α-amyrin, lupeol acetate, thiocarbamates and 
isothiocyanate (Taha et al. 2011; Ayyari et al. 2013). 
 
                        
ȕ-sitosterol,                                                    ȕ-sitosterol-3-O-glucoside                                         quercetin  
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         quercetin-3-O-rutinoside                                                   ȕ-amyrin                                               
           
                          (rutin)  
 
 
 
                                          
 
 
                α-amyrin                                                              lupeol acetate  
 
                                                  
                   Isothiocyanate                             O-organyl (1) and S-organyl (2) 
                                                                                                   Thiocarbamates 
 
 
 
 
 
In this work column chromatography was chosen as the main technique for the 
purification process of the ethyl acetate and chloroform extracts while other studies 
used vacuum liquid chromatography (VLC) for isolation of M.peregrina extracts. 
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Other separation techniques and identification methods includied preparative HPLC, 
TLC and NMR were also used in this project. 
 
8.2. Isolation of constituents from the EtOAc extract 
11 g of ethyl acetate fraction was prepared as described section 2.1.3 and 2 of of 
this study and separated by column chromatography on silica gel (250g). Two 
fractions were chosen from the eight on the basis of their purity, quantity and 
numbers of components - they had fewer constituents in comparison to other 
fractions according to their chromatograms. 
 
 
8.3. Fraction 4  
 From 11 g of Ethyl acetate the total of 20 mL fractions including F1 to F8 , were 
collected, after evaporating the solvents from the fractions , 1 g of fraction 4  (F-4, 1 
g) in semisolid form was obtained. F4 showed three UV active spots on the RP-TLC 
(MeOH/H2O 13:7) as shown in Fig. 3.1 .  
The purification of a portion of F-4 (400 mg) was achieved by preparative RP-HPLC 
using isocratic elution with ACN-H2O 40:60 (flow rate 6.0 mL/min, detection at 247 
nm) as mobile phase. Three main constituents were resolved (Figure 3.2).  
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Figure 3.1 Analysis of F-4. Fraction F-4 of Ethyl acetate fraction , before and after preparative HPLC. The right 
TLC  in normal phase could not separate resolve components of F-4 , shows as F4 in first lane  from right hand 
side, lane P4 presence O-butyl (2) 4-[(α-L-rhamnosyloxy  benzyl] thiocarbamate (E) , P3 shows 4(α-L-
rhamnosyloxy) benzyl isothiocyanate and P2  shows O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate (E) in  
Fig.31, the right TLC shows the three isolated compounds in normal phase, where all bands are almost have the 
same mobility while the left TLC  in Fig.3.1. is  in reverse phase ,number 5 shows F4 seperation , number 2 
shows O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate (E)),number 3 presence (4(α-L-rhamnosyloxy) 
benzyl isothiocyanate) and number 4 is for (O-butyl (2) 4-[(α-L-rhamnosyloxy  benzyl] thiocarbamate (E)). The  
left TLC, presents the three components found in F-4 ( shows in number 5 in left TLC) , the bands  in lanes 
2,3.and 4 are in the same level with their relevent  bands in lane 5 , meaning the separation method using 
preparative HPLC occurred successfully . The TLC plates were visualized at 254 nm.  
 
 
Further to TLC, Preparative HPLC was performed and revealed three separate 
peaks, named as 1, 2 and 3 (Fig. 3.2). Following analysis by NMR the structures was 
identified as described below. (Fig 3.3) 
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Figure 3.2. Preparative HPLC chromatogram of F-4. , using isocratic elution with ACN-H2O 40:60 (flow rate 6.0 
mL/min, detection at 247 nm) as mobil phase . NMR in DMSO-d6 solvent ,was used to identify the compounds 
from the peaks.  Peak 1 and 2 are thiocarbamate and 3 was the isothiocyanate the separation was monitored at 
247 nm.  
 
 
 
 
 
Figure 3.3 the structure of the O-ethyl (1) and O-butyl (2) 4-[(α-L-rhamnosyloxy  benzyl] thiocarbamate (E) in two 
resonance hybrids, a and b, and 4-(α-L-rhamnosyloxy) benzylisothiocyanate (3) 
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The structures of the three components fractionated by RP-HPLC are shown in 
Figure 3.3 and their identification is described below. 
 
 
8.3.1.The first compound, recovered from peak 1 of fraction 4  (compound 1) 
 
According to previous studies, when thiocarbamate phytochemicals were isolated for 
the first time from M. Oleifera two resonance hybrid forms, A and B in Fig. 3.4, were 
suggested (Faizi, 1992). This compound, O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] 
thiocarbamate (E) is also called niazimicin.The data for  1HNMR and 13CNMR were 
compared with previous NMR data from previous  study (Ayyari et al. 2014) and  the 
following data interpretation is suggested; 
 1HNMR data  are shown in section 1 of Table 3.1 . The compound has two triple 
gaps in the aliphatic region of 1.22,1.26  ppm and two mixed quadruples in the area 
of 4.41and 4.42  ppm, that indicate an ethoxy group in the molecule. The chemical 
shift of the NH group in the region of δ 9.45, also confirms the structure of s-trans 
two forms of resonance. The benzyl hydrogens chemical shift of NH and benzyl 
molecules in this structure were comparable with those of methoxy derivative forms. 
13CNMR spectrum in the area of 192.2 ppm indicates for ethyl thiocarbamate in 
Fig.3.6. 
The structure of these two hybrids resonance is shown in Fig. 3.4., Heating to 40 °C 
could not alter the structure of these two hybrids or produce only one form. Fig. 3.5 
shows the 1HNMR spectrum at 30 °C. 
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Figure 3.4 Structures of two forms of O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate (E)  
(niazimicin), isolated from the ethyl acetate extract of M.peregrina. The difference between these two  
molecules is the location of the double bond between C 8, N and S. In molecule A the double bond is between 
carbon number 8 and the nitrogen atom while in molecule B the double bond is between carbon number 8 and 
the sulphur atom.  
 
 
 
Figure 3.5 
1
H-NMR spectrum for compound 1 in DMSO-d6 solvent at 30
 
°C and 500 MHz. The analysis of 
the spectrum is discussed in the text. 
 
 
 
A B 
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Figure 3.6  13C-NMR  spectrum for compound 1 in DMSO-d6 at 125 MHz 
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Table 3.1 
1
H and 
13
C NMR spectroscopic data for thiocarbamates glycosidic 1 and 2 and 
isothiocyanate 3 (δ in ppm and J in Hz ). 
 
 
No   1  2  3 
  
1H 13C  1H 13C  1H 13C 
1    157.0   157.1   155.9 
2   6.99 (d, 8.5) a 117.6  6.99 (d, 8.6) a 117.5  7.07 (d, 8.6) 116.7 
   7.00 (d, 8.5) b 117.6  7.00 (d, 8.6) b 117.6    
3   7.24 (d, 8.5) a 130.2  7.23 (d, 8.6) a 130.2  7.31 (d, 8.6) 128.8 
   7.18 (d, 8.5) b 130.0  7.17 (d, 8.6) b 129.8    
4    133.1   133.1   127.9 
    133.0   133.1    
5   7.24 (d, 8.5) a 130.2  7.23 (d, 8.6) a 130.2  7.31 (d, 8.6) 128.8 
   7.18 (d, 8.5) b 130.0  7.17 (d, 8.6) b 129.8    
6   6.99 (d, 8.5) a 117.6  6.99 (d, 8.6) a 117.5  7.07 (d, 8.6) 116.7 
   7.00 (d, 8.5) b 117.6  7.00 (d, 8.6) b 117.6    
7   4.58 (d, 6.0) a 49.0  4.58 (d, 6.0) a 49.1  4.84 s 47.5 
   4.25 (d, 5.9) b 46.9  4.25 (d, 6.1) b 46.9    
8    192.2   192.4   128.9 
    190.6   190.8    
1'   5.35 (d, 1.5) 99.8  5.35 (d, 1.6) 99.8  5.39 (d, 1.6) 98.3 
2'   3.85 (dd, 3.6, 1.5) 72.1  3.84 (dd, 3.6, 1.6) 72.1  3.84 (dd, 3.6, 1.6) 70.1 
3'   3.67 (dd, 9.4, 3.6) 72.3  3.65 (dd, 9.4, 3.6) 72.3  3.65 (dd, 9.5, 3.6) 70.4 
4'   3.31 (t, 9.4) 73.9  3.30 (t, 9.4) 73.9  3.30 (t, 9.5) 71.7 
5'   3.51 (qd, 9.4, 6.1) 70.6  3.49 (qd, 9.4, 6.2) 70.6  3.46 (qd, 9.5,6.1) 69.5 
6'   1.12 (d, 6.1) 18.2  1.12 (d, 6.2) a 18.2  1.10 (d, 6.1) 17.9 
       1.11 (d, 6.2) b     
1"   4.42 (q, 7.1) a 67.1  4.37 (t, 6.7) a 71.1    
   4.41 (q, 7.1) b 69.35  4.36 (t, 6.3) b 72.2    
2"   1.26 (t, 7.1) a 14.88  1.64 (quin, 7.2) a 32.1    
   1.22 (t, 7.1) b 14.75  1.58 (quin, 7.2) b 31.9    
3"      1.37 (sex, 7.5) a 20.2    
      1.25 (sex, 7.5) b 20.2    
4"      0.91 (t, 7.5) a 14.3    
      0.85 (t, 7.4) b 14.2    
NH   9.45 (t, 6.0) a   9.45 (t, 6.1) a     
   9.46 (t, 5.9) b   9.49 (t, 6.1) b     
2-OH   4.99 br   4.92 br   5.07 br  
3-OH   4.68 br   4.60 br   4.76 br  
 
 
 
    
 
    
4-OH   4.83 br   4.76 br   4.89 br  
 
Table 3.1 
1
H and 
13
C NMR spectroscopic data for thiocarbamates glycosidic 1 and 2 and 
isothiocyanate 3 (δ in ppm and J in Hz ). 
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8.3.2.A second compound, recovered from peak 2 of fraction 4 (compound 2) 
 
Compound number 2 was another compound isolated from the extract that belongs 
to the thiocarbamate family. There are similarities between the analytical data of this 
compound with data from the previously isolated thiocarbamate compound in this 
project, (Table 3.1) including spectral characteristics, such as carbon, hydrogen, 
benzylic carbon, sugar group of α-L-rhamnose without acetyl, para-substitution of the 
benzyl ring with NH and carbon region of 194.4 ppm (Table 3.1).The only difference 
is that compound 2 has a busy aliphatic area that shows a chain with four carbons, 
n-butyl, in the molecule. A triplet in the area 4.37 ppm indicated that a CH2 of this 
group was bound to oxygen, which has a connection with carbon 71.07 ppm in the 
HSQC spectra. Similarity five in 1.64 , six in 1.37 and triple in 0.91 ppm related to  
other hydrogens of butyl group  that are bonded to carbons 14.30, 20.21 and 32/05 
ppm respectively. Hybrid resonance in these compounds can be seen clearly. This 
combination, as with the two other compounds, is s-trans type and the ratio of 
hybrids forms are 2.5 and 1. Form A constitutes a major form, and the compound 
was identified and named as O-Butyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate 
(E). 13C-NMR and 1H-NMR data are provided in table3.1. 
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Figure 3.7 Structures of two forms of O-Butyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate (E) isolated 
from the ethyl acetate extract of M.peregrina. 
 
 
Comparing the analytical data obtained for compound number 1 and 2 with data from 
previous studies (Ayyari et al. 2013) has confirmed the structures. Other details can 
be extracted from the data. 
For O-ethyl (1) and O-butyl (2) 4-[(α-L-rhamnosyloxy  benzyl] thiocarbamate (E) 
(compound number 1), the resonance hybrid proportion is 2 to 1 and resonance 
hybrid A is the main structure with molecular weight of 357.1246, calculated 
according to to its molecular formula,C16H23NO6S. 
For compound 2, O-Butyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate (E), the 
resonance hybrid proportion is 2.5  to 1 and resonance hybrid A is the main structure 
with molecular weight of 385.1559 calculated on the basis of  its  molecular formula 
C18H27NO6S . 
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8.3.3. A third compound, recovered from peak 3 of fraction 4 (compound 3) 
 
This is peak number 3 from the preparative HPLC of fraction 4 (Fig. 3.2) with a peak 
absorption of 1400.  The structure of this compound is different from two others. 
The spectrum in both the 1H-NMR and 13C-NMR in the area of sugar molecules are 
same. There was no evidence of carbonyl thiocarbamate in the area of 193 ppm, in 
the glycon part. In the 1H-NMR spectrum the hydrogen benzyl spectrum appeared 
slightly to the lower side in the area of 4.86 ppm. This molecules does not have 
hybrid resonance; it was as a single, pure component. The aromatic part of this 
molecule has a benzyl structure with para substitute same as the other two 
molecules. According to previous studies on the isolation of Moringa extracts 
(Dehshahri at el.2012),the spectral data are very similar. From that follows that the 
structure must be similar to the structure of isothiocyanate, also confirmed by carbon 
chemical shifts. Carbon number 8 in the structure of the isothiocyanate in the area of 
128.9 ppm appeared to be very weak. The spectrum for this carbon sometimes did 
not appear in the 13C-NMR spectrum therefore other scans were required to show 
the different spectra for this molecule such as HSQC, APT,13C-NMR, 1H-NMR (Fig 
3.9 to Fig.3.12). Spectrum data are shown in Table 3.1. 
The calculated molecular weight for this compound is 311.0827, and the weight of 
2M+H and 2M-H can be observed on the positive and negative mode of ITMS (Fig. 
3.13, Fig.3.14). 
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Figure 3.8 Structure of 4(α-L-rhamnosyloxy) benzyl isothiocyanate isolated from the ethyl acetate extract 
of M.peregrina. 
 
               
  
 
Figure 3.9 
1
H-NMR spectrum for compound 3 in DMSO-d6 at 500 MHz. 
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Figure 3.10
13
C-NMR spectrum for compound 3 in DMSO-d6 at 125 MHz. 
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Figure 3.11 APT  spectrum for compound 3 in DMSO-d6 at 125 MHz. 
 
Figure 3.12 Two dimensions HSQC spectrum, hydrogen carbon bond for compound 3 in DMSO-d6 . 
 
82 
 
 
             
Compound 3 is identified as 4-(α-L-rhamnosyloxy) benzyl isothiocyanate, and has 
known strong anti-bacterial effects, having been previously isolated form M. 
stenopetala, M. oleifera and M. peregrina (Eilert, 2007). 
 
 
 
 
 
 
 
 
Figure 3.13 The mass spectrum in plus mode of ITMS for compound 3 isolated from the ethyl acetate 
fraction of M.peregrina. 
 
 
 
 
 
 
Figure 3.14 The mass spectrum in minus mode of ITMS for compound 3 isolated from the ethyl acetate 
fraction of M.peregrina. 
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8.4. Fraction 8 
150 mg of fraction 8 (F-8) were separated by preparative RP-HPLC using isocratic 
elution with MeOH-H2O 45:55 (flow rate 6.0 mL/min, detection at 360 nm) as mobile 
phase and after completion of analysis by [1H-NMR and 13CNMR] two compounds 
were identified.  
  
 
    Figure 3.15 Separation of two flavonoids from fraction 8 of the ethylacetate extract of M. peregrina, 
detected at 360 nm, by preparative HPLC. 
 
  
5.4.1. First compound isolated from fraction 8 (compound 4) 
 
A fourth compound was isolated from fraction 8 using preparative HPLC (peak 1) 
and its flavonoid glycoside structure was identified on the basis of 13C-NMR in 
Fig.3.18, 1H-NMR shows in Fig.3.17 , ATP spectrum shows in Fig. 3.19 and Mass 
Spectrometry (MS) in Fig.  3.20 and Fig. 3.21 data .The UV analysis of this 
compound also confirmed the flavonoid structure. Hydrogens 6 and 8 with 2.0 Hz 
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shows the meta gap and as a result the substitution of carbon 5 and 7 was 
confirmed. If the sugar molecules were connected to carbon 7 then the chemical shift 
of carbon 2 would be transferred to 147 ppm; therefore the sugar molecules are 
connected to carbon  3 (in this case the chemical shift of carbon number 2 was 156/8 
ppm). The 1H-NMR spectrum shows another  three hydrogens in  the aromatic 
region,  a doublet for hydrogen 5 with a gap of 8.4 Hz has only one ortho neighbour, 
and hydrogen 6, which appears in the form of two doublets with gaps of 8.4 and 2.0 
Hz, shows two neighbours, ortho and meta. Hydrogen 2 with only one 2 Hz meta gap 
shows its connection with hydrogen 6. In the sugar part, glucose with a beta bond 
also attached to the flavonoid is confirmed with 5.4 shift in 7.4 Hertz gap. The 
rhamnose connection is in the alpha configuration as indicated by the 4.41 shift and 
the hydrogen anomeric gap of 1.1 Hertz. The carbonyl carbon and the methoxy 
group, appeared at 177.6 and 55.9 ppm, repectively. Carbon data and types of the 
carbons are listed in Table 3.2. Fig. 3.17 to Fig. 3.19 , show the spectra obtained by 
13C-NMR, 1H-NMR and APT for this compound. The chemical shifts of this 
compound are consistent with the name γˈ-methyl-quercetin-3-O-rutenoside. In 
flavonoids with two sugars attached to the glycon, rhamnose is always in the second 
position (Agrawal 1989).  
Figure 3.20 shows the molecule mass of 624.7 in the positive mode of ITMS related 
to M+H. In the negative mode of ITMS related mass to M-H was 623/8 (Figure 3.21). 
The structure of the molecule is shown in Figure 3.16 , Rutinoside is the connection 
between 1 from α-L-rhamnopyranosyl and 6-ȕ-D-glucopyranoside 
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     Figure 3.16  Chemical structure of 3ˈ-methyl-quercetin-3-O-rutinoside. 
 
1H-NMR and 13C-NMR data for compound 4, 3ˈ-methyl-quercetin-3-O-rutinoside 
(Fig.3.16, Fig.3.17). 
 
1HNMR (500 MHz, DMSO-d6) δ 7.83 (d, J = 2.0 Hz, 1H), 7.50 (dd, J = 8.4, 2.0 Hz, 
1H), 6.90 (d, J = 8.4 Hz, 1H), 6.43 (d, J = 2.0 Hz, 1H), 6.20 (d, J = 2.0 Hz, 1H), 5.41 (d, 
J = 7.4 Hz, 1H), 4.40 (d, J = 1.1 Hz, 1H), 3.82 (s, 3H), 0.95 (d, J = 6.2 Hz, 3H). 
13CNMR (125 MHz, DMSO-d6) δ 177.6, 164.5, 161.4, 156.9, 156.8, 149.6, 147.2, 
133.3, 122.6, 121.3, 115.5, 113.5, 104.3, 101.4, 101.2, 99.1, 94.1, 76.6, 76.1, 74.5, 72.0, 
70.8, 70.6, 70.4, 68.6, 67.2, 55.9, 17.9. 
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Figure 3.17 1H-NMR spectrum of compound 4 in DMSO-d6 at 500 MHz 
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Figure 3.18 
13
C-NMR spectrum in DMSO-d6 at 125 MHz 
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Figure 3.19  APT spectrum of compound 4 in DMSO-d6 at 125 MHz. 
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Figure 3.20  Mass spectrum of compound 4 in positive  mode of ITMS isolated from the ethyl acetate 
fraction of M.peregrina.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21  Mass spectrum of compound 4 in minus mode of ITMS from the ethyl acetate fraction of 
M.peregrina.  
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8.4.2. Second compound isolated from fraction 8 (compound 5) 
The next constituent was recovered from the second peak shown in Fig.3.15 . After 
removal of solvent a yellow solid was redissolved for HPLC analysis, the compound 
is substantially pure more than 90% purity , as indicated by a separate major peak.  
The observed UV pattern was the flavonoid pattern that usually appears, with two 
spaced peaks in the area of 265 and 366 nm (Fig. 3.22 upper right panel  and lower 
right panel).  
 
 
 
 
Figure 3.22 UV pattern of flavonoid structure for the second compound isolated from F8 (Compound 5).  
Right side of the panel shows flavonoid pattern ,including top right for two dimentions chromatogram 
and lower right for three dimentions UV pttern. Left side top is one dimention view of lower right of the 
panel  and lower left is a two dimentions chromatograms of top left. 
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In the 1H-NMR spectrum of compound 5, splits  are not  clearly identified  due to 
peaks from  sugers regions of the molecules, from 3 to 4 ppm  shows in Fig. 3.24 
,but on the basis of hydrogen chemical shifts and also 13C-NMR in Fig. 3.25  and 
ATP spectrum shows in Fig 3.26, identification of this compound could be 
completed. The absence of a methoxy group in the area of 55 ppm shows the 
difference between this molecule and 3ˈ-methyl-quercetin-3-O-rutnoside. 
Substitution of hydroxy instead of methoxy caused a chemical shift of some carbons 
in ring B. This compound was identified as rutin which is a combination of glucose 
ruteinoside and glycon quercetin. The chemical structure of the compound is shown 
in  3.23. The list of carbons and their chemical shifts for compounds 5 and 6 are 
shown in Table 3.2. These two compounds have been previously isolated from 
M.peregrina (Elbatran et al. 2005; El-Alfy et al. 2011). 
                                   
                                                          Figure 3.23 Chemical structure of compound 6 (rutin). 
 
The complete name of rutin is quercetin-3-O-α-L-rhamnopyranosyl-1-(1→6)-ȕ-D-
glucopyranoside. 
 
1H-NMR and 13C-NMR data for compound five (Rutin) 
1HNMR (500 MHz, DMSO-d6) δ 7.55 (dd, J = 8.3, 2.0 Hz, 1H), 7.54 (d, J = 2.0 Hz, 
1H), 6.86 (dd, J = 8.3, 2.0 Hz, 1H), 6.41 (d, J = 2.0 Hz, 1H), 6.21 (J = 2.0 Hz, 1H), 5.34 
(d, J = 7.0 Hz, 1H), 4.39 (d, J = 1.1 Hz, 1H), 0.99 (d, J = 6.1 Hz, 3H). 
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13CNMR (125 MHz, DMSO-d6) δ 177.3, 163.9, 161.1, 156.6, 156.4, 148.2, 144.6, 
133.2, 121.6, 121.1, 116.2, 115.1, 103.9, 101.1, 100.7, 98.6, 93.5, 76.3, 75.8, 74.0, 71.7, 
70.4, 70.3, 69.9, 68.1, 66.9, 17.6 
 
       
 
δ 13CNMR (ppm) 
 
Carbon 
number  
Compound 4 Compound 5 
C 2 156/8 156/4 
C 3 133/3 133/2 
C 4 177/6 177/3 
C 5 161/5 161/1 
CH 6 99/1 98/6 
C 7 164/5 164/0 
CH 8 94/2 93/6 
C 9 156/9 156/6 
C 10 104/3 103/9 
C 1' 121/3 121/1 
CH 2' 113/5 116/2 
C 3' 149/6 144/6 
C 4' 147/2 148/3 
CH 5' 115/5 115/1 
CH 6' 122/6 121/6 
CH 1" 101/4 101/1 
CH 2" 74/6 74/0 
CH 3" 76/6 76/3 
CH 4" 70/6 70/3 
CH 5" 76/1 75/8 
CH2 6" 67/2 66/9 
CH 1"' 101/2 100/7 
CH 2"' 70/4 69/9 
CH 3"' 70/9 70/4 
CH 4"' 72/1 71/7 
CH 5"' 68/6 68/2 
CH3 6"' 17/9 17/6 
OCH3 3' 55/9 
-
 
Table 3.2. Carbon data and types of the carbons for the first and second purified compounds from F8.                   
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Figure 3.24 
1
H-NMR spectrum  for rutin  in  at DMSO-d6 500 MHz 
The splits between 3 to 4 ppm are not cleare due to suger molecules. 
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Figure 3.25 
13
C-NMR spectrum  for rutin  in DMSO-d6 at 125 MHz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
 
 
 
 
 
 
Figure 3.26 ATP spectrum  for rutin  in DMSO-d6 at 125 MHz 
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 8.5. Isolation of constituents from the chloroform extract 
 
10 g of Chloroform fraction was prepared as described in section 1.3 and 
fractionated by column chromatography using silica gel (220 g).. Two fractions, C-4 
and C-13 were chosen for further study and identification of constituent molecules.  
 
8.5.1. First compound isolated from the chloroform extract (compound 6) 
The fraction C-4 from the hexane/ethyl acetate gradient at (85:15) gave a white 
precipitate (30 mg) after removal of solvent. It was confirmed by comparison with the 
standard of ȕ–sitosterol in our laboratory by TLC.  
 
 
 
Figure 3.27  Structure of β-Sitosterol and daucosterol isolated from chloroform extract of M. peregrina. 
 
 
8.5.2.Second compound isolated from the chloroform extract (compound 7) 
The fraction C-13 from the 95:5 part of the ethyl acetate/methanol gradient gave a 
white precipitate by adding methanol to the material concentrated from C-13. The 
TLC spot of the compound and the 1H-NMR and 13C-NMR analysis established the 
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structure as that of daucosterol, which is a glycoside of ȕ-sitosterol (3.7 mg, >97%, 
1H-NMR). 
Different NMR spectra of compound C-13 showed the structure of a steroid 
glycoside and the presence of a double signal in the region of 5/02 ppm with 
coupling index of 7.7 hertz are sign of beta anomeric proton connection in the region 
of 3.9 to 4.5.  
Proton of sugar glucose with other protons attached to an oxygen atom, was 
observed.  One olefin proton in the area of 5.34 ppm has appeared. 13C-NMR in 
pyridine solvent was therefore carried out and revealed a triple peak in the area of 
124,136,150 ppm, and two olefin carbons also at 141.4 and 122.4 ppm. One signal, 
related to the anomeric carbon, was seen at 103/0 ppm. Sugar carbons and one 
other carbon were seen in the region of 63-78 ppm (Fig. 3.26 and Fig. 3.27). 
According to the TLC spot, NMRs (Fig. 3.26 and Fig. 3.27) and ATP (Fig.3.28) data 
and reference standards available in the laboratory this compound was identified as 
ȕ-sitosterol-3-O-ȕ-D-glucoside or daucosterol, with the structure shown in Fig. 3.24 
,Daucosterol also had been isolated and identified from other plants in the past, 
including Phyllenthus emblica, Arctotis arctotoides and Cryptolepis obtuse (Paulo et 
al. 2000; Sultana, et al. 2007).   
 
 
Figure 3.28 Structure of daucosterol isolated from chloroform extract of M. peregrina. 
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Figure 3.29 
1
H-NMR spectrum for daucosterol in pyridine-d5 and  5% of CD3OD at 500 MHz. 
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Figure 3.30 
13
C-NMR for daucosterol, in pyridine-d5 with 5% of CD3OD at 125 MHz. 
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Figure 3.31 ATP spectrum for daucosterol in pyridine-d5 with 5% of CD3OD at 125 MHz. 
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In-Vitro Study 
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                                    Part I 
Glucose uptake 
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9.1.1. Introduction  
  
Generally, in vitro and animal studies that assess herbal and chemical compounds 
for potential anti-hyperglycaemic activity focus on measuring stimulation of glucose 
uptake (Hui et al.2009; Bösenberg et al.2008). The anti-diabetic compounds, 
including herbals and western medicines, may have different modes of action, but 
they all work to achieve the same goal, that is, restoring normal glucose levels in 
blood (Fig 4.1). 
 
 
Figure 4.1 Action sites of western medicine in diabetes treatment. Hypoglycaemic medicines restore 
euglycemia via several modes of action, including insulin secretagogues (sulfonylureas, meglitinides), 
insulin sensitizers (biguanides, metformin, thiazolidinedione), and alpha-glucosidase inhibitors 
(miglitol, acarbose). (Adopted from Bösenberg et al. 2008) 
 
Cells’ capability of glucose uptake, and its evaluation, plays an elemental part in 
diabetes research. There are different ways of assaying glucose uptake, for example 
using a labelled form of glucose to track uptake, as with 2-deoxy-[1,2-3H]-D-glucose 
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(Asano et al.1989; Mazibuko et al. 2011). Another approach is to measure glucose 
 content inside cells, or changes in glucose in cell media. The former requires a 
sensitive assay capable of measuring small changes in glucose, for example using 
glucose-oxidase (Wu et al. 2009). In our study we assessed the glucose uptake in 
HepG2 cells using 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose 
(2-NBDG), a fluorescent D-glucose analogue that produces detectable fluorescence 
when taken up by cells (Zou et al. 2005). This is a non-radioactive and non-invasive 
test for fast and direct evaluation of glucose uptake.  
 
 
9.1.2. Development of Glucose uptake Assay  
 
A previous study showed that when cells are treated with 2-NBDG concentrations 
higher than 0.25 mM, a high degree of self-quenching may occur, which would give a 
falsely low signal (Ball et al. 2002). Since it was the first time that 2-NBDG had been 
used in our laboratory , some preliminary experiments were carried out to optimise 
parameters for measuring 2-NBDG uptake, including 2-NBDG concentration, 
presence of glucose in the medium, incubation time and plate reader settings.   
 
9.1.3. Effect of 2-NBDG concentration and the presence of glucose 
 
HepG2 cells were seeded 2 x 105 cells in 0.5 mL full DMEM medium per well of a 24 
well plate.  Cells were allowed to grow overnight. 2-NBDG was added in methanol to 
final concentrations 1, 5, 10, 50 and 100 µM, with methanol at 1% (v/v) in all wells.  
Vehicle control cells received methanol only. Cells were incubated for one hour at 37 
°C and fluorescence measured immediately, using the bottom optic of the plate 
reader with ex 485 nm and em 530 nm, and without changing the medium. There 
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was no difference in the fluorescence between samples. This means that even 
though the reader was assessing fluorescence at the bottom of each well where cells 
will be attached, the differences in fluorescent signal between samples could not be 
differentiated. The 2-NBDG was still present in the medium, but even though cells 
were confluent, the fluorescent signal from the 2-NBDG in the medium was stronger 
than the cell signal and effectively masked detectable cellular uptake. 
Consequently the medium containing 2-NBDG was removed, cells washed once with 
PBS, then 0.5 mL PBS per well was added.  The fluorescence signal in cells was 
detected through the bottom optic of the plate reader and was about 30% higher in 
cells treated with 100 µM 2-NBDG compared with vehicle only.  The assay of 
glucose uptake in this conventional format was insensitive therefore as a next step 
the assay was modified by using medium with no glucose. 
In the next experiment HepG2 cells were seeded and grown as described above.  
The next day the full DMEM medium, which contains 5 mM glucose was replaced 
with glucose-free DMEM. 2-NBDG in methanol was added to final concentrations 1, 
5, 10, 50 and 100 M, with methanol at 1% (v/v) in all wells and 1% (v/v) methanol  
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Figure 4.2 Concentration dependence of 2-NBDG uptake by HepG2 cells 
Cells were incubated with indicated concentrations of 2-NBDG for four hours. Data are the mean ±SD of triplicate 
measurements, the uptake enhanced considerably when no glucose was present in the medium during treatment 
with 2-NBDG. 
 
only in control wells and cells were incubated for a further two hours.  The medium 
was removed, cells washed with PBS then 0.5 mL PBS added and fluorescence 
measured in the cells. The data (Fig. 4.2) show a clear trend of monotonic increase 
in RFU with concentration of 2-NBDG when no glucose is present.  Moreover the 
signal at the highest concentration of 2-NBDG is about 15 times higher than negative 
controls, compared with a 30% when glucose was present.  
In the next experiment the concentration dependence was re-assessed, this time 
using cells seeded at 1.2 x 106 / mL, 0.5 mL per well in 24-well plate and grown  as 
described in pervious experiment overnight.  This is a much higher concentration 
and cells were tightly confluent after overnight incubation. The full DMEM medium 
was replaced with glucose-free DMEM and then the cells were incubated with 2-
NBDG at 1, 5, 10 and 100 M for 4 hours at 37 °C.  The changes in assay condition, 
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Figure 4.3 Concentration dependence of 2-NBDG uptake in confluent HepG2 cells.  
Cells were incubated with indicated concentrations of 2-NBDG for four hours. Data are the mean ±SD of triplicate 
measurements. 
 
including incubation time with 2-NBDG and increased cell density led to a change in 
the trend (Fig. 4.3) compared with the previous experiment (Fig. 4.2), but at the 
highest concentration of 2-NBDG used, 100 M, the fluorescence increased about 
15 times higher than that of negative control. 
 
9.1.4.Time course measurement of 2-NBDG uptake   
In this assay HepG2 cells were cultured in a 24-well plate and incubated overnight. 
The medium was replaced by glucose free medium and 100 µM of 2-NBDG in 
duplicate wells at time points: 0, 30, 60, 90 minutes.  At 90 minutes medium was 
removed from all wells and washed once with PBS, then fluorescence was 
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Figure 4.4 Time-course of 2-NBDG uptake by HepG2 cells.   
Uptake of 2-NBDG was monitored in cells incubated with DMEM containing 2mM pyruvate and 100 M 2-NBDG. 
Data are mean ±SD of duplicate measurements. The data indicate maximal uptake of 2-NBDG within 15 min.       
 
measured (Fig. 4.3). 2-NBDG uptake was maximal by 15 min. 
In view of these preliminary findings, the assay of glucose uptake was carried out 
routinely with glucose-free medium, 2-NBDG at 100 M and with an incubation with 
2-NBDG for 15 min. Although it is possible that higher concentrations of 2-NBDG 
could have been used to improve sensitivity, it was too costly to do so routinely. 
9.1.5. Effect of extracts of M.peregrina on glucose uptake by HepG2 Cells 
 
2- NBDG uptake by HepG2 cells was used to evaluate the potential anti-diabetic 
effects of Moringa peregrina extracts. HepG2 cells were treated with six different 
types of M. peregrina extracts for one hour then incubated with 2-NBDG for 15 
minutes. After incubation, free 2-NBDG was cleared from cultures and fluorescence 
associated with the cells was measured in a fluorescent reader. The results are 
presented as the mean+S.D. of six independent experiments in triplicate (Fig. 4.4). 
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Figure 4.5 Effect of six extracts of M.peregrina on glucose uptake by HepG2 cells. Glucose uptake was 
measured in HepG2 cells after treatment with 5µL of 10mg/ml of each M.peregrina extracts for one hour. The 
results are mean ±S.D of five independent experiments in triplicates. Asterisks indicate p<0.05 (*) or p<0.005 
(***) compared with control, determined by t-test or by one-way ANOVA. 
The data demonstrate the effect of six extracts of M.peregrina on glucose uptake in 
HepG2 cells, of which EtOAc is the most effective extract, stimulating a 2.5 times 
increase on glucose uptake with respect to control. Methanol, hexane and 
chloroform extracts increased glucose uptake 2.1, 1.9 and 1.5 times, respectively, 
compared with control.  The water extract induced only a 20% change in glucose 
consumption with respect to control and the effect of the butanol extract was 
negligible with respect to control. 
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9.1.6.Comparison of short term and long term treatment of three active 
extracts of M.peregrina (Hexane, CHCl3, EtOAc) on glucose uptake in confluent 
HepG2 cells 
 
To understand the mechanism of stimulation of glucose uptake in HepG2 cells by M. 
peregrina extracts, we designed two experiments. A short-term treatment of HepG2 
with the extracts and a long-term treatment. HepG2 cells were grown over three 
days to ensure confluency and the medium was replaced with fresh medium every 
day. The three active extracts of M. peregrina (Hexane, CHCl3 and EtOAc) were 
added for one hour then 2-NBDG uptake was assessed. A second batch of HepG2 
cells were treated with the three extracts for 24 hours after which 2-NBDG uptake 
was measured. The data, shown in Fig. 4.5, revealed that there is a significant 
difference between duration of the treatments of HepG2 cells with active extracts of 
M.peregrina with short term treatments being more effective than long term 
treaments. The one hour treatment with the chloroform extract increased the uptake 
around three times more than control (300%) and the ethyl acetate extract increased 
uptake by approximately 70%, whereas the hexane fraction showed about 10% 
improvement in the uptake in respect with control. After 24 hours treatment  
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Figure 4.6. Effect of M. peregrina extracts on glucose uptake by HepG2 cells after short and 
long term treatments.  Glucose uptake was monitored in confluent HepG2 cells incubated with ethyl acetate, 
chloroform or hexane extracts for short term (1 hr) or long term (24 hr) treatments. The results are mean+S.D. of 
four independent experiments in triplicate. p**** < 0.0001 for differences in duration of treatment as determined 
by two-way ANOVA.  
 
the chloroform extract increased the uptake by about 30%, the ethyl acetate by  less 
than 15% and there was almost no effect from hexane extract on glucose uptake. 
Analysis of the data by two-way ANOVA confirmed that there was a significant 
difference (p<0.0001) in glucose uptake between the two periods of treatment. The 
quick acting effect of the extracts suggests that the mechanism of action does not 
involve modulation of gene expression at the level of transcription. Instead there 
could be a post-transcriptional effect involving modulation of glucose transporter 
expression at the protein level. HepG2 cells, in common with many cancer cells, 
have a high capacity for glucose metabolism due to a high requirement of generating 
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energy by aerobic glycolysis, often called the Warburg effect. The possibility of 
regulation of gene expression as a major mechanism of action of the extracts has 
been eliminated. Instead the data raise the possibility that levels of glucose 
transporter, or transporter activity have been modulated. This could involve 
translocation, but the main glucose transporter of HepG2 cells, GLUT1, does not 
undergo an insulin-dependent translocation regulation. such a mechanism previously 
was shown for other anti-diabetic drug like  insulin in osteosarcoma cells (Cifuentes 
et al. 2011).  
 
 
9.1.7.Evaluation of effect of known anti-diabetic drugs against active extracts 
of M.peregrina   
 
To test the effectiveness of M.peregrina on glucose uptake in HepG2 cells a 
comparison was carried out between the extracts and known ant-diabetic 
medications, both synthetic and phytochemical, including metformin, berberin and 
ouabain, and using phloretin as a negative control. HepG2 cells were seeded at a 
concentration of 0.5x105 cells/mL, incubated  overnight then treated with  ethyl 
acetate, chloroform and hexane extracts of M.peregrina and  anti- diabetic 
compounds as described in chapter 2 and incubated for one hour. The  required  
concentrations for the known anti-diabetics and phloretin and was found from 
previous studies, including 10µM for berberine (Yeb et al.2012), 0.1 mM for 
metformin (Jacobs et al.1986), Ouabian (Reid 1996), 1 mM  of ouabain (Kajikawa 
et al. 2002) and 200µM of phloretin (Wu C.H.,et al. 2009). In one hour treatment, 
normal DMEM medium replaced after one hour incubation  by glucose free 
medium, then  5 µL of β-NBDG  added into three wells in each row in order to have 
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γ wells as a control. After incubation for 15 minutes, the cells were washed with 
PBS and fluorescent intensity measured using an Omega FLUOStar plate reader.  
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Figure 4.7. Effect of M.peregrina extracts and known anti-diabetic drugs on glucose uptake in 
HepG2 cells. Uptake of 2-NBDG was measured in HepG2 cells incubated with metformin, ouabain, 
berberin, and ethyl acetate and chloroform extracts of M.peregrina, and phloretin. The data are mean 
+S.D. of four independent experiments in triplicate. p**** < 0.0001, difference between the means of treatments 
compared with control are statistically significant as determined by one-way ANOVA. 
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According to the data presented in Fig. 4.6  all treatments stimulated glucose uptake  
and the most effective anti-diabetic agent that stimulates glucose uptake after one 
hour is berberin with a 167% increase with respect to control ,followed by metformin 
and ouabain with 145% and 138% respectively. The EtOAc extract of M.peregrina 
proved to have the highest effect among all the treatments in this experiment, with 
210% increased on glucose uptake compare to control while chloroform and hexane 
appeared to have the least effect on glucose uptake in compare to rest of the 
treatment, with 102% and 106% respectively in respect to control. An inhibitory effect 
of phloretin was not observed in this assay.  Instead, it too stimulated glucose uptake 
quite markedly, by about 150%. 
 
9.1.8.Evaluation of phytoestrogens effect on glucose uptake in HepG2 cells. 
 
In previous studies consumption of phytoestrogens in the human diet and their effect 
on human health have been investigated (Adlercreutz et al .1997; Anderson et al. 
1998; Setchell et al.1998; Anthony et al.1998; Tham et at.1998; Lissin et al. 2000; 
Velasquez et al.2001). Due to structural similarity between this biologically active 
group of phytochemiclas and the structure of estradiol, phytoestrogens bind to 
estrogens receptors and apply estrogenic and antiestrogenic effects (Martin et 
al.1978; Wang et al. 1996; Kuiper et al. 1998; Miksicek et al.1994). These plant 
derived compounds can be divided in three major types including, isoflavones, 
lignans, and coumestans. The two most common phytoestrogens in the human daily 
diet are isoflavones and lignans, and one of the rich sources of isoflavones are soy 
beans with approximately 0.2% isoflavones content (Reinli et al. 1996). A number of 
trials have been done in type 2 diabetic patients to evaluate the effect of 
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phytoestrogens, mainly isoflavones, on diabetes management (Jayagopal et al. 
2002; Azadbakht et al. 2008; Hermansen et al. 2001; Liu et al. 2009; Clerici et al. 
2011; Anderson et al. 1998; Teixeira et al. 2004; Gobert et al. 2010). 
The most bioactive isoflavones include genistein and daidzein, that are derived from  
biochanin A and formononetin. We used our current optimised method of monitoring 
glucose uptake to measure the hypoglycaemic effect of genistein , daidzein and 
formononetin in HepG2 cells. 
 
9.1.9.Glucose uptake measurement in HepG2 cells treated with daidzein 
 
HepG2 cells were cultured and seeded in a 24 well plate at a concentration of 
0.5x105 cells/mL, and the next day the cells were treated with 5µL diadzein with six 
different concentrations, started from 10-4 M to 10-9M. For short-term treatments the 
cells were incubated only for one hour after treatment, while for long term treatment 
the cell were treated for 24 hours. After the treatment period the medium was 
replaced with glucose free medium and 2-NBDG added. The measurement was 
performed after 15 minutes of incubation with the fluorescent analogue. 
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Figure 4.8. Effect of daidzein on glucose consumption in HepG2 cells.  Uptake of the fluorescent 
glucose analogue 2-NBDG was measured in HepG2 cells treated with daidzein forr short and long term periods 
at the indicated concentrations and compared to control untreated cells. The data are mean+S.D. of three 
independent experiments in triplicate. p**** < 0.0001 comparing duration of treatment, p****<0.0001 comparing  
daidzen with control, as determined by two-way ANOVA.  
 
 
 
The data (Fig. 4.7) show that daidzein stimulates uptake of glucose, with a greater 
effect after a short treatment of one hour compared with tretament 24 hours.  The 
effect was broadly higher at the lower concentrations tried, 1 M to 1nM, at which 
glucose uptake was increased four to five fold after a one hour treatment.  
Interestingly the higher concentrations tried, 10 and 100 M, showed less effect. 
Longer treatments resulted in a lesser stimulation of glucose uptake, and a peak 
effect was found at 0.1 M.   
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9.1.10.Glucose uptake measurement in HepG2 cells treated with genistein 
 
Another isoflavone phytoestrogen that was used in this study was genistein. HepG2 
cells were cultured at 0.5x105 cells/mL, incubated overnight, and then treated with 
5µL genistein with range of concentrations starting from 10-4 M to 10-9M, for one hour 
or 24 hours. 
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Figure 4.9. Evaluation of genistein on glucose uptake in HepG2 cells. Glucose consumption test was 
performed in HepG2 cells treated with range of genistein concentrations from 10
-4 
M to 10
-9
M,  for  one hour and 
24 hour compared with untreated control . The data are mean+S.D. of three independent experiments in 
triplicate. p**** < 0.0001 comparing duration of treatment, p****<0.0001 comparing genistein with controls 
determined by two-way ANOVA.  
 
The data (Fig. 4.8) indicated much less effect of genistein compared with diadzein. 
Generally one hour treatments had a slight inihibitory effect compared with control, 
with the exception of treatment at 1 M, which stimulated uptake about htree-fold 
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compared with control. Longer treatments with 10-4M to 10-6 M genistein resulted in 
gradual increase in glucose uptake to 2.4 times more than control, and thereafter a 
decline. Overall there was significant difference in glucose uptake between short and 
long term treatements,as indicated by two-way ANOVA, but the differences depend 
on the concentration of genistein, with higher concentrations of 10 and 100 M 
inducing greater uptake after 24 hours treatment but at lower concentrations, uptake 
was stimulated more after a one hour treatment. 
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 9.1.11.Glucose uptake measurement in HepG2 cells treated with formononetin 
 
Formononetin is the last isoflavone phytoestrogen that was studied in this project. 
The hypoglycaemic effect of this compound was assessed in the same way as the 
two others. 
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Figure 4.10. Effect of formononetin effect on glucose uptake in HepG2 cells. Glucose uptake measured in 
HepG2 cells after short and long treatments with six different concentrations of formononetin compared with 
untreated control. The data are mean+S.D. of three independent experiments in triplicate. p**** 0.0001 
comapring duration of treatment, p***<0.0001 as determined by two-way ANOVA.  
 
A short treatment with formononetin inhibited glucose uptake (Fig. 4.9), while longer 
treatments had varaible effects, with an aprroximately two fold stimulation across a 
range of concentrations.    
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                                                       Part II 
                    Glucose consumption 
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9.2.1.Introduction 
 
The glucose uptake studies described in part one showed the effect of M.peregrina 
extracts on glucose uptake in HepG2 cells as assayed using a short kinetic method 
that gives a relative measure of the uptake capacity of the cells at the time of 
measurement. It was of interest to see whether treatments with extracts of 
M.peregrina would affect glucose consumption to a measurable degree, by 
assessing changes of glucose concentration in the cell culture medium. A 
glucometer was used, based on a glucooxygenase strip, which had a 
measurement range of 0.5 to 22 mM. 
In the series of experiments described in this section, changes in glucose levels 
were monitored in the cell culture medium of HepG2 cells after 2 to 48 hours of 
treatment with two M. peregrina extracts, prepared with ethyl acetate or chloroform.  
The extracts are compared with metformin, a drug used to treat diabetes, which is 
known to act by stimulating glucose uptake in the liver and peripheral tissues.  In the 
work described here it is assumed that there is no involvement of insulin in the 
mechanism of action – no exogenous insulin is added.  
To model diabetic levels of glucose, HepG2 cells were grown in full medium 
containing 11mM glucose.  To take into account variations in cell numbers in the 
wells of the 24-well plate, cells were counted in each well, by trypsinisation and 
counting with a haemocytometer, after measurement of glucose. The changes in 
glucose in the medium are used to calculate glucose uptake and are normalised to 
500,000 cells.  There was not much variation in cell numbers between samples, 
since for most measurements cells were allowed to grow to near confluency. 
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9.2.2.Two hour treatments 
 
In these experiments HepG2 cells were seeded as previously described and 
incubated overnight, and then the medium was replaced with 0.5ml of fresh full 
DMEM medium with glucose concentration of 11mM and treated with 5l of each 
M.peregrina’s extract (10mg/ml) in DMSO, 10l of 5mM metformin in DMSO, and 
one set of wells received DMSO only as a vehicle control. The rest of the wells 
received no treatment. The cells were then incubated for two hours and the glucose 
level in the medium was measured using the glucometer. 
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Figure 4.11 Glucose consumption measurement in HepG2 cells treated with ethyl acetate chloroform and 
metformin after two hours treatment.  Effect of two active extracts of M.peregrina, metformin and DMSO only 
was evaluated in HepG2 cells for two hours treatment compared with untreated control. The data are mean+S.D. 
of two independent experiments in triplicate. p****< 0.0001 comparing treatments with control, as determined by 
one-way ANOVA. Data are expressed as decrease in glucose concentration in cell culture medium, normalised 
for cell number. The  glucose uptake data shows in the graph as normalised per cell count. 
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Data from two  independent experiments are shown in Figure 4.10.    
Cells incubated for two hours with extracts of M.peregrina showed a marked 
increase, with an average of 42%, in glucose consumption compared with 
unstimulated controls.  At this time point metformin had slight increase with around 
8% in glucose uptake and differences among means are statistically significant (p < 
0.0001).The effect from metformin  explains its mechanism of action that  is 
expected to start usually after 24 hours (Miyoshi et al. 2014, Mitsuhashi et al.2014, 
Luo et al.2012 
 
9.2.3. 24 hour treatments 
 
In this part of the work HepG2 cells were cultured and treated with the two extracts 
as described in the previous section. After 24 hours incubation of HepG2 with the 
treatments there is a trend towards increased glucose uptake (Fig. 4.11), and this 
time metformin induced a similar response to the Moringa  extracts, a 52% increase 
in glucose consumption with respect to control. The ethyl acetate and chloroform 
moringa extracts produced about the same level of stimulation. 
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Figure 4.12 Glucose uptake measurement in HepG2 cells treated with ethyl acetate and chloroform 
extracst from Mroinga, and metformin, for 24 hours treatment.  Evaluation of hypoglycaemic effect of two 
active extracts of M.peregrina, metformin and DMSO only was tested in HepG2 cells for 24 hours treatment 
compared with untreated control. The data are mean+S.D. of two independent experiments in triplicate. p< 
0.0001 as determined by one-way ANOVA comparing means of treatment with DMSO or control. Data are 
expressed as decrease in glucose concentration in cell culture medium, normalised for cell number. 
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9.2.4. 48 hours treatment 
 
The glucose uptake measurements were repated on cells treated for 48 hours with 
either Moringa  extracts or metformin.  The Moringa extracts were still active, 
producing an overall stimulation of glucose uptake, after 48 hours, whereas the  
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Figure 4.13. Effect of ethyl acetate and chloroform extracts from Moringa,and metformin, on 
glucose uptake in HepG2 cells compared with control after 48 hours treatment.  Glucose 
consumption was measured with a glucometer. The data are mean+S.D. of two independent 
experiments in triplicate. p****< 0.0001 as determined by one-way ANOVA  Data are expressed as 
decrease in glucose concentration in cell culture medium, normalised for cell number. 
 
 
effect of metformin was no longer apparent, when compared with control.   
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9.2.5. Time course effect of extracts on glucose uptake in HepG2 cells 
 
The data from the glucose consumption measurements was combined (Fig. 4.13) 
Shows the effect of the extracts of M.peregrina started immediately and continues 
after 24 hours and 48 hours and the effect of metformin started within 24 hours of 
treatments with continues decrease to 48 hours. Statistical analysis, two-way 
ANOVA, shows a  significant difference between the effect of the treatments at 
different time points (p****< 0.0001) and between the treatments also is significant 
(p****<0.0001). t-test , comparing ethyl acetate with contro (p**<0.01) and chloroform 
with control (p**<0.01) ,showed significant difference between the treatments with  
active extracts compare to control . 
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Figure 4.14. Time course overview for effect of two active extracts of M.peregrina (prepared using ethyl 
acetate or chloroform) compared with metformin and untreated control on glucose uptake in HepG2 cells 
for 2, 24, 48 hours of incubation with treatment. The effect of active M.peregrina extracts prepared using ethyl 
acetate or chloroform, metformin or DMSO on consumption of glucose from the cell culture medium over two, 24 
and 48 hours. Data are expressed as decrease in glucose concentration in cell culture medium, normalised for 
cell number.  The data are mean ±S.D of three experiments with six replicates. P**** 0.0001 for duration of 
treatment, P****<0.0001 for concentration  as determined by two-way ANOVA. 
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9.2.6. Western Blotting  
 
The western blot is a widely used analytical technique to detect specific proteins in 
samples such as cell extracts. HepG2 cells after incubation with treatment extracts 
for 24 hours were lysed using lysis buffer.  The protein content of each lysate was 
measured using the BCA assay and 20 µg of protein from each lysate was analysed. 
Proteins were blotted to nitrocellulose membrane after completion of electrophoresis 
according to standard protocol as described in part II.   GLUT1 protein was detected 
using primary anti-glut1 antibody and secondary anti-body solution of anti-rabbit IgG 
labelled with horse-radish peroxidase (HRP). 
The bands were detected in all loaded lanes as a single band in the region of 50kDa 
as expected molecular weight for GLUT1 (Fig 4.14), although the quality of the blot 
precludes a clear analysis but the impression is that the EtAc fraction increases 
GLUT1 expression. 
 
 
Figure 4.15. GLUT1 expression in HepG2 cells.  GLUT1 is detected in the region of 50kDa in HepG2 
cells. Extracts from cells treated with DMSO (lane 1), two active extracts of M.peregrina (prepared using 
ethyl acetate or chloroform) (lanes 2 and 3 respectively), DMSO (lane 4) and unstimulated controls (lanes 
5 and 6). 
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The gel was analysed using ImageJ software to compare the expression of GLUT1 
in each sample, by selecting a rectangular region around each band and quantifying 
the intensity of each sample (Fig. 4.15).  These data are a preliminary analysis and   
 
 
Figure 4.16.  Quantitation of expression of GLUT1 in HepG2 cells. A plot of the intensity of the 
bands of GLUT1 from the image of the blot shown in Fig. 4.14, quantified using ImageJ.  
 
suggest that both extracts from M.peregrina could stimulate an increased expression 
of GLUT1. However these are data from a single experiment and although care was 
taken to load equal amounts of protein from each extract, the data do not take into 
account a control for the blotting and detection process, such as measurement of -
actin. 
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Metabolic Activity Measurements using a Seahorse 
XF
e
24 Analyser 
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9.3.1. Analysis of the effect of three Moringa compounds 
on HepG2 metabolism 
 
A Seahorse Bioscience XFe24 Extracellular Flux analyser was used in this part of the 
project to measure the oxygen consumption rate (OCR) and glycolysis within the 
HepG2 cells as indicators of primary metabolic activity though glycoysis and 
oxidative phosphorylation. Three compounds purified from the two active extracts of 
Moringa peregrina were selected, chosen as representative of the three classes of 
phytochemical identified in the extracts, namely a thiocarbamate (O-ethyl 4-[(α-L-
rhamnosyloxy) benzyl] thiocarbamate (E)) and a flavonoid (rutin) from the EtOAc 
extract and a sterol (-sitosterol) from the CHCl3 extract.  
Cells were incubated with the three compounds or vehicle control for two hours 
before the start of the experiment.  
The Seahorse XF analyser is a platform for metabolic assays which, simultaneously 
and in real time, measures the two major energy producing pathways of the cell, 
mitochondrial respiration and glycolysis, in a microplate. The analyser measures 
oxygen consumption rate (OCR) as the indicator of mitochondrial respiration, and 
extracellular acidification rate (ECAR) which is predominately the result of glycolysis, 
at intervals of approximately 2-5 minutes. We evaluated the oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) in HepG2 cells after two hours 
incubation with control, 8µM [O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate 
(E)], γ0 µM ȕ-sit and 10 µM (rutin) over a period of 30 minutes in three replicates per 
group, to investigate functional transformation in glycolysis and mitochondrial 
respiration. 
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The Thermo Scientific™ Pierce™ BCA Protein Assay is a detergent-compatible 
formulation based on bicinchoninic acid (BCA) for the colorimetric detection and 
quantitation of total protein. This method had been used to measure the protein level 
of the cells for normalising the data from the Seahorse experiment. 
The standard curve of the assay is shown in Fig. 5.3.1. and the mean protein 
content. 
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Figure 5.3.1.  Standard curve of BCA protein assay. The line represents the best linear fit.. The dotted lines 
either side represent linear regression for the entire set of standard points.  
 
of cells grouped according to treatment are shown in Fig. 5.3.2.  The treatments did 
not induce any significant changes in proteins content, as indicated by comparison of 
means by ANOVA or by student’s t-test comparing treatments with control (p>0.05). 
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 Figure 5.3.2.  Protein content of HepG2 cells groups in the Seahorse analysis after treatment of 
HepG2 cells with β-sitosterol, MA4P2 (O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate 
(E))and M8P2 (rutin). Data from the BCA assay using the standard curve in Fig. 5.3.1, and the mean+SD 
of five cell replicates, each sampled for the assay in triplicate. There are no significant differences 
between the means as assessed by one-way ANOVA and student’s t-test comparing treatments with 
control. 
   
In order to assess the mitochondrial metabolic capacity of the cells maximal 
respiration can be measured. This in turn is linked to spare respiratory capacity and 
mitochondrial ATP production. These three sets of measurements, derived from 
measuring oxygen consumption in the presence of appropriate inhibitors (described 
in chapter 2), are presented in Fig. 5.3.3. There are no significant differences 
between treatments and control (one-way ANOVA and student’s t-test give p>0.05). 
One mechanism that could account for increased glucose consumption could be 
increased metabolism through the TCA cycle which is uncoupled from ATP 
generation.  This is a well known mechanism by which energy metabolism can be 
increased, resulting in an increase in heat rather then ATP. Known uncouplers 
include 2,4-ditrophenol and FCCP, but these compounds are either potentially or 
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actually toxic.  If a herbal or other treatment acts by this mechanism it must do so in 
a mild way otherwise it would be toxic.  
When the measurements of basal respiration and proton leak are examined it 
appears that some significant effects of the Moringa compounds have occurred. 
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Figure 5.3.3. Effect of selected Moringa phytochemicals on mitochondrial energy metabolism in HepG2 
cells. Oxygen consumption rate measurement of maximal respiration (upper chart), ATP production (middle 
chart) and spare respiratory capacity (lower chart) after treatment of HepG2 cells with ȕ-sitosterol, MA4P2 (O-
ethyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate (E))and M8P2 (rutin).  
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Figure 5.3.4. Effect of selected Moringa phytochemicals on non-mitochondrial resipiration in HepG2 cells. 
Oxygen consumption rate measurement of non-mitochondrial respiration after treatment of HepG2 cells with ȕ-
sitosterol, MA4P2 (O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate (E)) and M8P2 (rutin). ȕ-sitosterol 
induces a significant increase in oxygen consumption compared with control (student’s t-test p<0.01). 
 
The effect of the Moringa  phytochemicals on non-mitochondrial respiration is shown 
in Fig. 5.3.4.  ȕ-Sitosterol significantly increases the rate of oxygen consumption, by 
about 15%, compared with control (student’s t-test p<0.01), and O-ethyl 4-[(α-L-
rhamnosyloxy) benzyl] thiocarbamate (E) ,does this too, but not quite significantly 
(student’s t-test p=0.053). These effects are not likely linked to energy metabolism 
and may reflect an increase in P450 metabolic activity that may be induced by the 
phytochemicals. 
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Basal respiration is defined as the normal rate of mitochondrial oxygen consumption, 
made up of two components, ATP production (oxidative phosphorylation) and 
leakage of protons across the mitochondrial membrane  - the latter causes 
consumption of oxygen because the protons are generated by the TCA cycle and 
electrons also donated to the electron transport chain will combine with oxygen and 
protons to form water. 
The effect of the Moringa  phytochemicals on basal respiration and leakage of 
protons is shown in Fig. 5.γ.5.  ȕ-Sitosterol causes a significant increase, by 38%, in 
basal respiration compared with control (student’s t-test p<0.05). Since there are no 
significant differences in ATP production amongst the groups, the increased basal 
respiration could reflect an increase in proton leakage induced by ȕ-sitosterol. This 
turns out to be the case. Both ȕ-sitosterol and rutin cause a significant (student’s t-
test p<0.05) increase in proton leakage, by 56% and 49% respectively. This effect is 
the largest found in any of the measurements made in this experiment. 
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Figure 5.3.5. The effect of Moringa phytochemicals on mitochondrial basal respiration and proton leak. 
Oxygen consumption rate measurement of mitochondrial basal respiration and proton leak after treatment of 
HepG2 cells with ȕ-sitosterol, MA4P2 (O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] thiocarbamate (E)) and M8P2 
(rutin). Significant increases in oxygen consumption compared with control (student’s t-test p<0.01) are indicated 
by asterisks. 
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10.1. Discussion and conclusion  
                              
 
The data from this part of the project have guided us about hypoglycaemic effect of 
M.peregrina extracts and phytoestrogens.  Data from optimisation of the method of 
use for 2-NBDG as fluorescent glucose analogue in glucose uptake assay was the 
first data generated in this project, and it helped us to determine the most suitable 
concentration for 2-NBDG in terms of its effect and cost which is 100 µM. Also cell 
concentration and types of medium with/ without glucose (Fig.4.1, 4.2 and 4.3) and 
incubation time were established. After deploying the optimised method to the first 
experiments for evaluation of M.peregrina extracts on glucose uptake in HepG2 cells 
(Fig.4.4) the most effective extracts in stimulating glucose uptake were identified, 
namely those made with ethyl acetate, chloroform and hexane.  These extracts 
induced an increase in glucose uptake that was significant with respect to control 
(p<0.05 for ethyl acetate, chloroform and hexane extracts) while the effects of the 
three other extracts were not significantly different compared to control. Although the 
methanol extract appeared to make a significant difference on uptake with respect to 
control, the standard deviation was high (p= 0.710, methanol vs control). We then 
focused on the three active extracts and have tested their effect on glucose uptake 
as assyed using 2-NBDG, after long term and short term treatments.  We chose to 
use confluent cells for this part of the assay to make the model similar to the 
quiescent phase of hepatocytes in liver. The data in Fig 4.5 shows that the 
treatments exerted more effect on glucose uptake after one hour compared with 24 
hours treatment. According to a two-way ANOVA test the difference between the 
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duration treatment in this test is significant (p< 0.0001) and the difference between 
the treatments also is significant (p<0.001). 
As the effect of M.peregrina extracts on stimulation of glucose uptake had been 
shown using the 2-NBDG assay it was of interest to compare the effect with well-
known anti-diabetic drugs metformin, berberin and ouabain, and with, phloretin, a 
known inhibitor of glucose uptake. The ethyl acetate extract expressed the highest 
effect on stimulating of glucose consumption among all the treatments while 
chloroform and hexane extracts were less effective, they however increased the 
uptake, on the basis of a one-way ANOVA, differences between the means are 
statistically significant (p<0.001). 
Measurement of glucose consumption was the second method to analyse the 
efficacy of the extracts. The finding from these experiments Fig. 4.10-Fig. 4.14 also 
showed the effectiveness of the ethyl acetate and chloroform extracts as the most 
potent in modulating glucose consumption. The data also confirmed that the best 
effect was achieved with a short term treatment and there was not  much change on 
stimulation of  glucose consumption after 24 and 48 hours treatment with ethyl 
acetate or chloroform extracts. In Fig 4.10, metformin data revealed that there is no 
effect from metformin on glucose uptake after a short treatment, while after 24 hours 
treatment Fig 4.11, shows the efficacy of metformin which is in line with its known 
pharmacokinetics, which was not observed in 48 hours treatment Fig.4.12. 
 
On the basis of our findings in this study, the hypoglycaemic effects of M.peregrina  
ethyl acetate and chloroform extracts was confirmed with two different methods  
(Fig.4.4 and Fig.4.10). Further in vitro investigation with these methods indicate that 
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the two active extracts of M.peregrina are fast acting with no increase in their 
efficacy with longer incubation time (Fig.4.5 and Fig 4.13).  Therefore an increase in 
gene expression could not be a mechanism by which an increase in glucose uptake 
is induced. It suggests a fast-acting mechanism is operating for example the 
translocation or stabilisation of glucose transporters. 
Since the active extracts from M. peregrina  had been identified, it became important 
to isolate and characterise the components in them. Following purification of the 
ethyl acetate and chloroform extract as fully described in chapter 3, seven  
components were identifed, three of which, O-ethyl 4-[(α-L-rhamnosyloxy) benzyl] 
thiocarbamate (E), ȕ-sitosterol  and rutin were chosen to be investigated for further 
investigation for more clarification of their mechanism of effect. As the extract 
assessed for their anti-diabetic effects, a study was designed to assay  the 
components’ effect on HepG2 cell metabolism.  
Previous  studies showed  anti- diabetic, hypotension  and antioxidant effect of  
Moringa species  specially M. peregrina (Ullah et al. 2015, Ullah et al. 2016, 
Dehshahri et al. 2012) and M. oleifera (Gupta et al. 2012),Bennett et al. 2003), 
different parts of this plant use as vegetables in many countries which is relevant to 
the effects of this plant on many diseases. 
Ullah and his team investigated hypoglycaemic effect of hydro-alcoholic extract of 
M.peregrina by using in-vitro  enzyme model to assess inhibitory effect of three 
important enzymes in diabetic treatment including α-amylase, α-glucosidase and 
dipeptyl peptidase 4.the results of inhibitory effect on pancreatic α-amylase  showed 
persistent intervention of the extract with action of the enzyme in response to 
increasing the concentration of the extract with IC50 value of 1,335.89 μg/mL. Values 
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reported are ± SEM of three independent experiments*P ≤ 0.05, * *P ≤ 0.01 
significant when compared with the control (in the absence of tested concentration of 
the extract), this inhibitory effect leading to decrease in glucose absorption and 
lowering the postprandial serum glucose levels. 
 The data from analysis of M.peregrina inhibitory effect on Dipeptidyl peptidase-4 
(DPP4) revealed that the extract regularly inhibited the enzyme function in a dose-
dependent manner with IC50 value of 1,218.12 μg/mL. Values reported are ± SEM of 
three independent experiments*P ≤ 0.05, * *P ≤ 0.01 significant when compared with 
the control (in the absence of tested concentration of the extract). The inhibitory 
effect improves glucose homeostasis by achieving longer half-life and biological 
activity for Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic 
polypeptide (GIP). 
 
 
Oxidative stress is an etiological factor for diabetes mellitus hence it is trusted 
antidiabetic treatment may contain anti- peroxidative/cytoprotective potential. 
Antioxidant effect of Moringa as a part of human dietary in many countries was 
assessed using ABTS+ radical scavenging assay. The data showed M. peregrine 
extract led to continuous scavenging of ABTS+  radical in a dose dependent manner 
with IC50 value of 20.56 μg/mL and the positivity of the assay were due to  presence 
of components that were isolated from the extract such as; tannins , phenolics and 
saponins.Values reported are ± SEM of three independent experiments*P ≤ 0.05, * 
*P ≤ 0.01 significant when compared with the control  (Ullah et al. 2015).They also 
evaluated hypotension effect of M.peregrina by examining its inhibitory effect against 
142 
 
angiotensin converting enzyme (ACE) that is one of the critical enzyme in 
management of hypertension and cardiovascular disease, in this study  dose-
response of M. peregrine extract with  R. stricta, M. Peregrina and A. fragrantissima 
was tested and the results showed the increase of ACE  inhibitory activity with 
increase in the extract concentration. Captopril as ACE inhibitor drug was used as a 
standard in this experiment, IC50 values presented the ACE inhibitory effect of the 
extracts in the following order, R. stricta > M. peregrina > A. fragrantissima. Values 
reported are ± SEM of three independent experiments. *P ≤ 0.05: significant when 
compared with the control  (Ullah et al. 2016). 
Dehshahri and her colleagues studied antioxidant effect of phenolic group as one of 
the major constituents using he DPPH radical scavenging assay. The data revealed 
that M. peregrina leaf extract reduced DPPH radicals significantly as compared to 
the control (P<0.05). The extract showed IC50 value of 8.06 ± 0.β9 μg/ml compared 
with polyphenol, EGCG from green tea, which was used as the positive control with 
IC50 value of 1.54 ± 0.19 μg/ml. The extract was significantly (P<0.05) less active 
than EGCG. There were significant differences (P<0.05) between DPPH scavenging 
activity of different concentrations of extract except γ0 and 40 μg/ml (Dehshahri et al 
2012) 
Adisakwattana and his team studied other Moringa species including M. oleifera. 
Anti- diabetic and hypolipidemia effect of the extract was evaluated by testing its 
inhibitory effect on of alpha-glucosidase and pancreatic alpha-amylase . M.oleifera 
extract contained a specific inhibitor of intestinal sucrose than intestinal maltase with 
IC50 value of 0.78 +/- 0.21 mg/ml, values reported are ± SEM of three independent 
experiments*P ≤ 0.05, significant when compared with the control. Considering it 
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slightly inhibited pancreatic alpha-amylase and pancreatic cholesterol esterase, the 
extract did not show inhibitory effect on pancreatic lipase. Results indicated that the 
leaf extract of M. oleifera may be used for the control of blood glucose and lipid 
concentration and prevention of hyperglycaemia and hyperlipidaemia 
(Adisakwattana and Chanathong 2011). 
Sangkitikomol and his colleagues determined total antioxidants and inhibitory effect 
of Moringa oleifera extract (MOE) on AGE formation using the ORAC assay, the 
FCP assay, and the total flavonoids assay. HepG2 cells treated with varying 
concentrations of MOE (0 - 10 mg/mL; 0 = control) was evaluated using AGE 
formation assay and amino guanidine was used as an inhibitor. Values are reported 
as means with their standard error (SE). All experiments were performed in triplicate 
(N = 3). *P < 0.05 for significant change in AGE formation as compared to control 
(untreated)  (Sangkitikomol et al. 2014). 
In this current work we also have focused on a phenolic (isoflavone) group as well as 
thiocarbamates and phytosterols (ȕ-sitosterol). 
ȕ-sitosterol was previously isolated from the chloroform extract  as a major 
component of the aerial parts of Aristolochia indica (CEAI). Excellent anti- diabetic 
effect of CEAI was shown through in vitro as well as animal study. The efficacy of the 
extract was compared with standard drug, Glibenclamide (10 mg/kg p.o.) in diabetic 
mice. Antioxidant effect of the extract in the level of 1, 1- diphenyl-2-picrylhydrazyl 
(DPPH) and superoxide radical with IC50 value being 7.325 and 8.498 µg/ml, 
respectively. The data showed that A. indica has anti-diabetic property as well as 
high level of natural antioxidants ( Sanjay et al. 2012). 
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Another traditional herbal medicine that has been studied intensively for treatment of 
diabetes is Momordica charantia. Some researchers investigated effect of M. 
Charantia aqueous leaf extract on fasting blood glucose (FBG), where administration 
of the M. Charantia aqueous leaf extract in the diabetic rats  significantly (p<0.05) 
reduced  FBG  level after two and four weeks treatment in compared to untreated 
diabetic control in dose-response manner (Sani et al.2015). Numbers of studies have 
suggested its mechanism of anti-diabetic effect through stimulation of peripheral 
glucose utilization , inhibition of gluconeogenesis, stimulation of key enzyme of HMP 
pathway and conservation of islet ȕ cells and their activity (Hasan et al.2012, Joseph 
et al. 2013).Due to multitude medical conditions that can M.charantia treat , 
scientists were interested to study its bioactive compounds ,charantin, polypeptide-p 
and vicine were isolated as main compounds with hypoglycemic effect  from 
M.charantia (Joseph et al. 2013). 
 Charantin hypoglycemic effect in fasting rabbits showed gradual decrease in blood 
sugar level within one to four hours and recovered slowly to initial level. Blood sugar 
level was dropped  by 42% at the 4th hour with oral dose of 50 mg/kg .The average 
blood sugar decline during 5 hours was 28%. Charantin was found to be more potent 
than tolbutamide nonetheless both compounds have changed blood sugar level in 
the same way (Desai et al. 2015). Charantin is steroidal glycoside and exist as equal 
mixture of stigmasterol glucoside and ȕ- sitosterol glucoside (Pitiphanpong et al. 
2007).These information are supporting the usage of isolated phytoestrol (ȕ-
sitosterol) from our extracts for testing its effect on HepG2 cell metabolism. 
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An isoflavone was studied as one of the isolated compounds from M.peregrina 
extracts and as a member of the phytoestrogen family in this project.  
Seahorse bioanalysis was chosen to measure effect of the constituents on oxygen 
consumption rate in HepG2 cells. Beta-sitosterol and O-ethyl 4-[(α-L-rhamnosyloxy) 
benzyl] thiocarbamate (E) have shown an increase trend in maximal respiration, non-
mitochondrial respiration and spare respiratory capacity while there was no change 
for  oxygen consumption rate in ATP production . 
As we use cancer cells for our experiment (HepG2 cells) and after taking into 
consideration Otto Warburg’s finding in cancer cell metabolism (Koppenol et al. 
2011), that cancer cells have increased aerobic glycolysis (the so-called “Warburg 
effect”) (Michelle et al.2013), the outcome of the Seahorse assay can be supported 
in the sense that there should not occur any changes in mitochondrial respiration as 
in tumour cell aerobic glycolysis is the main pathway of energy production. 
 
Analysing the hypoglycaemic effect of phytoestrogens was next part of this work 
where we applied the optimised method for usage of 2-NBDG to assess glucose 
uptake effect of the phytoestrogens. HepG2 cells were treated with Isoflavones 
phytoestrogens including daidzein, genistein and formononetin and each treatment 
was separately performed and analysed. The daidzein data, Fig.4.7 revealed that in 
both modes of study the uptake were stimulated and all the concentrations exerted 
increased effect on the uptake. However a better effect came from short term 
treatment, and concentration of 10-9 M is the most potent treatment. With genistein 
(Fig. 4.8) the situation is different, as in both modes of study, the change in glucose 
uptake fluctuated. In the one hour test the only concentration of genistein that 
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showed an increase effect on the uptake was 10-6 M and it was about 2 times more 
than control. The rest of the concentrations did not have a positive effect on glucose 
consumption in HepG2 cells. In long treatments only two of the genistein 
concentrations appeared to have a positive effective on modulating the uptake, 10-6 
M and 10-5 M. 
The information from formononetin assay and its effect on glucose uptake (Fig 4.9), 
shows that only the long term method of treatment can stimulate the consumption of 
glucose, where the lowest concentration 10-9 M is the most potent compared with the 
rest of concentrations, and increased the uptake around 2.5 times more than control. 
The effect of phytoestrogens, mainly in type 2 diabetes, have been extensively 
studied previously (Jayagopal et al. 2002; Azadbakht et al. 2008; Hermansen et al. 
2001; Liu et al. 2009; Clerici et al. 2011; Anderson et al. 1998; Teixeira et al. 2004; 
Gobert et al. 2010). In this work we assessed the effect of daidzein, genistein and 
formononetin on glucose uptake in an in vitro study. The finding in this section in 
terms of the isoflavones’ hypoglycaemic effect is supported by previous studies. 
 
The aim of the western blotting part of this study was to analyse the effect of our 
extracts on expression of GLUT1 in our model hepatocellular carcinoma cell line. 
Previous studies on the expression of GLUT1 in human and rat HCC tissue had 
different outcomes. In most studies a strong and increased expression of GLUT1 
had been found in HCC (Yamamoto et al. 1990; Grobholz et al.1993). While other  
studies failed to detect GLUT1 protein expression by immunohistochemical staining 
in HCC tissue (Su et al. 1990; Younes et al. 1996; Zimmerman et al. 2002; Burke 
et.al.2002; Roh et al.2004). We designed an experiment to establish Western 
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blotting technique for our targeted protein GLUT1. On basis of the results from the 
experiment we could see that the bands was detected in all loaded lanes as a single 
band in the region of 50kDa as were expected. These data show the GLUT1 was 
detected and the GLUT1 transporters are abundantly expressed in HepG2 cells.  
The effect of the active extracts was assessed once and very preliminary data 
suggest they may increase expression. 
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